Podcasts about Boston Scientific

Meta admits its Social Media is harmful to kids with $18B settlement, Meta Glasses now will stop working if you block the Recording light, Boston Scientific and McKesson Breached, Microduck Robot the next big thing? Flock OS Investigate tool getting creepy, CISA warns that Software vendors need to focus more on Secure by Design.

The U.S. disrupts a Chinese hacking operation blamed for intrusions at several sensitive government agencies.  CISA says more than 100 water systems were targeted in July. Attackers exploit a critical Gitea flaw, while malicious pages masquerade as Cloudflare verification screens. Cyber insurance claims get costlier, and AI agents break out of their sandboxes. Boston Scientific battles a cyber incident. Plus, a new standard tracks AI agent activity, criminals target stolen iPhones, and an alleged money mule is charged in a $7.5 million scam. Our guest is Stephen Hilt,  Sr. Threat Researcher at TrendAI,  on the risks facing data centers.  Some breach data doesn't quite measure up. Remember to leave us a 5-star rating and review in your favorite podcast app. Miss an episode? Sign-up for our daily intelligence roundup, Daily Briefing, and you'll never miss a beat. And be sure to follow CyberWire Daily on LinkedIn. CyberWire Guest On today's Industry Voices, we are joined by Stephen Hilt,  Sr. Threat Researcher at TrendAI discussing the cybersecurity risks facing data centers and the thousands of internet-exposed industrial control systems that could leave them vulnerable to attack. And if you enjoyed this conversation, be sure to check out the full interview here.  If you'd like to hear more on this topic from TrendAI, you can check out this recent episode of the AI Security Brief podcast that focuses on data center security. Guest Mark Houpt, CISO at DataBank, joined hosts Johnny Hand and Dustin Childs to explain why securing the AI era starts with protecting the physical data centers that power it—and why proven security fundamentals still matter against rapidly evolving threats. AI Security Brief podcast publishes every other Thursday on the N2K CyberWire network. Subscribe today! Selected Reading China-sponsored hacking platforms seized by US, Justice Department says (Reuters)   CISA: Over 100 Internet-Exposed Water Systems Targeted in July Cyberattacks (SecurityWeek) Hackers now exploit critical Gitea flaw in code injection attacks (Bleeping Computer) Hackers abuse npm mirrors to host phishing redirect pages (Bleeping Computer) Average Cyber Insurance Losses Increase Despite Fewer Claims (Infosecurity Magazine) VMs won't contain cyber-capable agents (Trail of Bits) Boston Scientific hit by cyberattack, global operations affected (Reuters) Linux Foundation Introduces TRACE Standard for AI Runtime Evidence (Infosecurity Magazine) AnonyMousKIT PhaaS uses voice AI agents to phish iPhone passcodes (Bleeping Computer) Indian man who fled US arrested on charges he helped scammers siphon $7.5 million from the elderly (The Record) Trump signs memo to help drastically boost US commercial space launches (Reuters)  A Cautionary Tale About Data Breach Claims, Verification and Carhartt (Troy Hunt) Share your feedback. What do you think about CyberWire Daily? Please take a few minutes to share your thoughts with us by completing our brief listener survey. Thank you for helping us continue to improve our show. Want to hear your company in the show? N2K CyberWire helps you reach the industry's most influential leaders and operators, while building visibility, authority, and connectivity across the cybersecurity community. Learn more at sponsor.thecyberwire.com. The CyberWire is a production of N2K Networks, your source for strategic workforce intelligence. © N2K Networks, Inc.

Ohne Aktien-Zugang ist's schwer? Starte jetzt bei unserem Partner Scalable Capital. Mit eigenem KI-Chatbot, der dir alle Fragen rund ums Investieren beantwortet. Alle weiteren Infos gibt's hier: scalable.capital/oaws. KI-Chips unter Druck. Goldpreis auf Hoch seit Mai. Alibaba sammelt 10 Mrd. $ für KI. YMTC plant IPO. Xpeng baut Roboter-Sparte auf. Trump will 50% Autozoll auf Kanada. Porsche zahlt 1,3 Mrd. € an Tata für KI. NVIDIA will Perplexity-Anteil. Aktie von Boston Scientific (WKN: 884113) hat 50% verloren. Die zwei Wachstumsmotoren Farapulse und Watchman schwächeln. Aber der CEO kauft für 9 Mio. $ eigene Aktien. Turnaround oder Falle? Klaus-Michael Kühne ist verstorben. Sein 49 Mrd. $ Imperium liegt in einer Stiftung. Wie kam es dazu und wie geht es jetzt weiter? Kühne + Nagel (WKN: A0JLZL), Hapag-Lloyd (WKN: HLAG47), Lufthansa (WKN: 823212), Brenntag (WKN: A1DAHH). Wie geht's weiter? Diesen Podcast vom 25.08.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us Fan MailJohn MacMahon is a serial entrepreneur specializing in early-stage product development. Beginning with Kerberos Proximal Solutions, he has led and/or founded numerous medical device startups in the vascular field. John was the COO for Maya Medical and led their transfer of manufacturing from the US to Ireland. He was also the General Manager for Europe for Claret Medical (acquired by Boston Scientific).Presently, John is the CEO and co-founder of CytoKind, where they are expanding the research on the benefits of increasing exposure to narrow-band UVB light (NB-UVB), and is the CEO of Mitre Medical. John is an active mentor for entrepreneurs from Stanford BioDesign, Enterprise Ireland, and the Kauffman Foundation.He received his Bachelors in Physics at the University of California, Santa Cruz, and graduate studies in both electrical and biomechanical engineering at Stanford University (MS EE).Our skin is specifically tuned to absorb NB-UVB light, which starts a natural cascade of actions that calms the immune system and reduces inflammation for better health. In psoriasis, for example, NB-UVB performs as well as Humira clinically, and outperforms it in patient quality of life satisfaction.Find John at-https://cytokind.net/Find Boundless Body at-myboundlessbody.comBook a session with us here! 

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Denis Johnson, Chief Executive Officer at Grand River Aseptic Manufacturing.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Denis, covering: What his time in the military and the CDMO industry have in common Why he is passionate about operations, and why operational excellence is the real product CDMOs deliver His decision to leave a successful leadership role at Catalent and move to the customer side of the industry Realising his ambition of becoming a CDMO CEO, and why sterile fill finish remains such an attractive area of the market The case for staying focused in small molecules rather than trying to become a “Swiss Army knife” provider Why sterile manufacturing continues to be one of the biggest pain points in pharma launches and commercial supply   Denis Johnson brings extensive life sciences leadership and manufacturing experience to his role as CEO, including significant prior sterile fill-finish experience. He has led operations and commercial senior leadership roles in the biologics, pharmaceutical, and combination devices for over 25 years. Before being appointed CEO at Grand River Aseptic Manufacturing, his prior roles include Head of Global Manufacturing and Technical Operations at Biogen as well as leadership roles at Catalent, Boston Scientific and Johnson & Johnson. He started his career in the U.S. Army managing logistics and operations.   Denis earned a B.S. in Economics from the University of Wisconsin Madison and an MBA from the University of South Carolina.   Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

Dave Rosa shares how a lifelong drive to help others and his own health challenges led him into 32 years across orthopedics, cardiovascular, and neuro. Dave walks through his path from early marketing roles to becoming a CEO, and explains the innovation behind NeuroOne's electrode platform designed to combine diagnosis and treatment in a single procedure—starting with epilepsy, expanding to trigeminal neuralgia, and now targeting lower back pain. He also discusses early work using the same technology for precise drug delivery to the brain, including a program focused on glioblastoma. Dave closes with leadership lessons on vision, culture, learning from mistakes, and giving back.    Guest links: https://nmtc1.com/ | https://www.linkedin.com/company/n1mtc/ Charity supported: Opportunity International Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host & Editor: Lindsey Dinneen Producer: Velentium Medical   EPISODE TRANSCRIPT Episode 086 - Dave Rosa [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome back to another episode of The Leading Difference podcast. I'm your host, Lindsey, and today I'm delighted to welcome as my guest, Dave Rosa. Dave is an entrepreneur with three decades of experience in the medical device industry, spanning a variety of technologies and products. In addition to CEO roles with early-stage medical device companies, Mr. Rosa's background also includes senior roles with C.R. Bard Inc., Boston Scientific Inc., and St. Jude Medical, where his responsibilities included marketing, product development, and business development. He has been named as an inventor on multiple medical device patents, serves on seven corporate boards, and has raised 200 million in the capital markets. Well, Dave, thank you so much for being here today. I am absolutely delighted to have you on the show. [00:01:33] Dave Rosa: Well, thanks for having me. [00:01:34] Lindsey Dinneen: Yeah, of course. I would love, if you wouldn't mind, by starting out and just telling us a little bit about yourself, your background, and what led you to medtech? [00:01:45] Dave Rosa: Yeah. So, born and raised in a small town called Richport, Pennsylvania, outside of Philadelphia. And really was in love with the medtech industry from the time I was much younger. So I, I have been in medtech now, it's going on 32 years and that's everything from large medical device companies to, to startup companies. I've been in so many different areas of medtech. I've been in orthopedics, cardiovascular, and I mean everything involving the heart, I've been in it in some way, shape, or form, a-a-as well as neuro, which is what I'm in now. And, and I think, you know, why did I get into medtech? I think this all goes back to when I was a little kid. You know, I, I was the little kid that was walking street people to my house and bringing them into my home for my mom to make a meal. I don't know that she always appreciated that me doing that, but, but there, there were more than enough times where she sat me down and I was maybe only four or five years old, and she's like, "Honey I, I, I know you wanna help people, but you can't bring everyone home." And I was like, "Oh, oh, you know, okay, Mom." Of course, until the next time. But, you know, I think it started at an early age and, and really has carried through you know, the rest of my career [00:03:07] Lindsey Dinneen: Yeah. Yeah, okay. So you've always been interested in helping people, and you've had a really nice variety of experiences within medtech. But tell us about your path from that early just interest and care in, in people and their wellbeing, to perhaps your educational journey and maybe, like, the first little bit of your career that led you to where you are now. [00:03:32] Dave Rosa: Yeah. So, in high school I was involved in sports and, and even prior to high school, and I had so many physical issues. So I had initially a shoulder problem that was I'll, I'll say pretty complicated, at least back in those times. And what I found is by the time I got to college, and, you know, I'm still trying to figure out what I wanna do with with my life and what career I wanna take. I, I was actually in chemical engineering, but came, came to the conclusion that I hated chemistry, which, which didn't help things out. And, and I really knew, you know, my, my passion was on the medical side, and a lot of it, you know, was driven because of my own issues, my own shoulder issues, because it really put a damper on, you know, any, any potential I had at especially playing baseball. So, so, i- in college, I went to Drexel University, there really wasn't a course for biomedical, undergraduate biomedical engineering that was, like, a graduate program. And, you know, I, I decided that I would take courses in electrical engineering and a program called commerce and engineering, which kinda merges both the business and engineering side of the equation. So, I, I actually started out not in medical. I was in electrical engineering, and I was probably one of the worst electrical engineers working at Westinghouse at the time. And I remember one of the managers saying to me, he's like, "You know, all, all the other engineers and marketing people really like working with you. Why is that?" And I said, "I, I really don't know other than, you know, I've always been a passionate person about whatever I'm doing." So, you know, so at that point, I started thinking that engineering was not the path for me, that you know, that I was really more, much more passionate about medical because it was impacting my life with my shoulder. And then by that time, you know, my knees and everything else started to go as well. But I graduated with a degree in commerce and engineering, and then after working a few years in electrical engineering for Westinghouse Electric I just started knocking on doors because I, I really-- my passion was, you know, helping others, and I wanted to be involved in an area that might help me being orthopedics. So that, that's kinda how I got my first job, knocking on doors, and Stryker Instruments decided they would take a chance on me, and that, that was kind of the beginning. [00:06:12] Lindsey Dinneen: Very nice. And so when you found medical device, was it this really exciting moment of realizing that it could marry your interests in engineering and your desire to help people? Was that like just this cool moment of going, "Oh, wow, like I, I can do both"? [00:06:31] Dave Rosa: Yeah. I, I, you know, I remember actually praying about this, like, "What am I supposed to do?" Like, you know, and, and "How do I go about this?" And I don't know, you know, it, it, it brought back some memories you know, of when my father was you know, was at the end of his life, and he was this stern Italian man. Never, you know, never-- there, there was no discussion about feelings or anything like that. It was like, "You do what I tell you to do. You, you talk when I tell you to talk. Otherwise, you know, you say nothing." So my, my dad's literally on his deathbed, and he says to me, "You know, I, I really wanna thank you, son, for taking care of your mother and I all these years with, you know, medical decisions." And he said, "You know, you, you always were helping people from the time you were a little boy." And it actually stunned me that my dad, who never appeared to be paying attention to anything regarding me, was like, "Hey, you know, you, you know, you really cared about helping people, not just us, but, you know, this, this goes back to the beginning for you." So it, it was also more of a reinforcement of like, "Yeah, I've, I've really gotta be in medtech, and I'm gonna start with, you know, how I can help my own issues and/or, you know, family's members' issues that they may have." [00:07:52] Lindsey Dinneen: Mm-hmm. Yeah. Yeah. I think sometimes we don't realize the impact that we're making at the time and being able to just do what we feel is right and, and what we know helps others can actually make an impact, and then hopefully we get those opportunities like you got with, with your father to s- realize eventually, "Oh, okay, yeah, I, I am, I am on the right path doing, doing the right thing at this time." So yeah, it's great to have those moments of reinforcement, but. [00:08:26] Dave Rosa: And if you fast-forward, you know, to something again, just more reinforcement, although it's much later in my career and I've had other moments like this, but this was just last month. I was at, at a memorial service for one of the physicians that used our product to treat a, a young lady, she was 17 years old at the time for epilepsy. And so the doctor that performed a procedure on her had a tragic accident, passed away, and we were all at this memorial service for him. And the father along with the mother and, and this young lady who's now in college, they came up to me you know, we were, you know, just chatting about how unfortunate the situation is. And when I got ready to, you know, go back to the service he said to me "Sir, I, I just wanna thank you for giving my baby girl her life back." And I mean, those kinds of things, when, when people say those things to you, and like I said, it's happened more than once, and, and it's because of something, you know, that you've you know, committed the, the company to accomplishing, and then you see results like this, there's nothing more rewarding than that. [00:09:39] Lindsey Dinneen: Yeah, of course. Yeah. Thank you for sharing that. So, all right, so in fast-forwarding a little bit you, you started in medtech with Stryker, and then what gave you-- and, and there's probably maybe some things in between-- but what gave you the the idea for what you're doing now? And can you just take us along that journey from starting out in medical device to where you are now, including that just pathway to even, to even higher roles in leadership and that learning curve as well? [00:10:12] Dave Rosa: Yeah, that's-- boy, that's a long story when you've been in it for 30-some years. You know, I, I started out in marketing. I always liked the interaction between customers, meaning, you know, physicians, patients, when, you know, we had the opportunity to, you know, to speak to the patient. And then, you know, I, I I would like to think that maybe some of my decision-making and, and some of my ideas, you know, led to success in some of these companies. And you know, I think upper management you know, wa-was able to identify that I might have some of the, the qualities that they were looking for really in the next generation of leaders. And this goes back to you know, my, my first job in the cardiovascular industry. Gosh, this was in 1995, so, about 30 years ago with Boston Scientific. And I was able to go from a Product Manager to a Director of Marketing. And I was there for a total of about four years, and I, I really enjoyed the strategic part of the job, and I, I wanted to be more involved in that. And I got an opportunity to go to a startup to run sales and marketing also in the cardiovascular space. And that was a, a great experience because, you know, in smaller companies, and this, by the way, was my first opportunity in a smaller company, you know, you, you have to wear a lot of hats. And I liked, I always liked to be more hands-on and still am, to be honest, and, you know, th-this gave me an opportunity to really you know, get involved in more than just what the job detail or the job description called for. And, you know, the-these things all, sometimes, you know, require some luck but definitely, you know, the right timing. And an opportunity in the startup company that I left Boston Scientific for became available at the CEO level, and the the investors-- the company was funded by venture capitalists-- met with me and said, "You know, we, we think you can take the company to the next level." And I think that was back in 2003, and pretty much been a CEO ever since then. But I, you know, I think a lot of the success comes from and confidence from, you know, the, the hiring companies. I, I think what people notice about me is my passion, my, my commitment, and, and probably the fact that you know, I, I think one of the things I'm strong with is developing a, a, a vision. I mean, that's, that's something that I think is really critical with leaders is that you, you've gotta develop a vision for the company, a strategy for the company so that others can understand what the goals are. So that, that's kinda my path. It's, you know, it's, it's I would say every four to five years I've had an opportunity to either start a company or run a company. And then NeuroOne, which is, you know, my current company, I was actually retired when I was approached by a few individuals who had this idea. And what started out as me just, you know, helping them turned into "Gosh, we would love you to run the company." And I really thought there was an opportunity there, you know, to help people who suffered from these neurological disorders, primarily brain-related disorders. But, you know, that, that vision has kind of expanded beyond just the brain into other areas of the body. [00:13:56] Lindsey Dinneen: Wow. Yeah. Okay, yeah. I appreciate you sharing more about your journey. I love the fact that you're both an engineer and you have this creative side with marketing, and you're able to marry all that together. That's, that's really cool, and gives you such a unique perspective on, you know, I would say product development and then commercialization. But okay, so let's talk about your company now, and what are you excited about? What are some of the innovations coming out of it? You mentioned that it sort of s- it started in one place and one focus, and now we get to see it expanding. And so I'd just love to hear all about your company as well. [00:14:33] Dave Rosa: Sure. So, we started out with the intention to develop this electrode technology, and initially it was primarily to be used for brain-related procedures for patients, initially at least, that were suffering with epilepsy. And this, this technology, the, the idea was "Let's combine functions with this" in that it, it, it would have the ability to perform a diagnostic function. And for these patients, the diagnostic function was finding the area in the brain that was triggering these issues. And then once you were able to accomplish that, then using the same device, destroy that brain tissue that was causing the problem in an effort to eliminate the seizures that patients were having. So that, that's kind of where we started. We, we are selling that technology. We have a distribution partner, Zimmer Biomet, that is our exclusive distributor for that technology, and we've had great success in treating patients. You know, the story that I told about the father you know, who thanked me for getting his daughter's life back, that's what that technology is used for. And the-- really what patients had to face before this technology was available is they would have to have a very invasive surgery just for the diagnostic part of the procedure. So the part where you're just trying to identify the problem area, that was one surgery. And we're, we're talking about, you know, drills that are drilling holes, you know, through the skull with these devices being placed in the brain. And then once that part was done, the patients would go home, and they would be scheduled for a follow-up procedure where they would have to come back again, have an invasive procedure in-into the brain, and then that, that second procedure would be the one where they would eliminate or destroy the problematic brain tissue. So if you're a patient, two invasive surgeries, two hospitalizations, two separate devices, and we said, "Why can't you do it with one?" And, and that's, that's where we are. We then more or less leveraged that technology to treat a a condition called trigeminal neuralgia, which is this excruciating facial pain that patients will experience. And it, there-- it's very well known to carry a a high rate of suicide because of how painful this condition is. But we were able to leverage the same system and provide the neurosurgeon you know, with, with a very unique tool to treat that condition. We also-- what I'm also excited about is these-- the, the same platform we're using now to develop technology to treat lower back pain. There's different types of lower back pain. We, we happen to be focusing on two. One that involves issues with the basivertebral nerve, which is a l- a nerve in the lower spine. And then the more common back pain where you have pain that's traveling down the leg, that's sciatic nerve pain. So we've been able to use the same electrode to to develop technologies, unique technologies that would be able to treat that condition. And then finally, drug delivery. These electrodes have a hollow center and we've been able to demonstrate in animals so far that not only can you use it for diagnostics and stimulating through, but you can also deliver therapeutic agents directly into the brain, specifically where you would like to deliver them. And we, we've initiated a program to try to improve really the care for patients that suffer from glioblastomas, which are those brain tumors that carry high rates of mortality. [00:18:45] Lindsey Dinneen: Wow. Wow. Well, there is an incredible amount of innovation coming out of the company, and I'm so excited to follow along and just see all of the difference that you're gonna make in patients' lives. So gosh, first of all, thank you for what you're doing. I, I'm curious, you know, you, you've had such a great career and so many different opportunities to grow into more and more leadership roles. And I, I'm wondering, first of all, what your own leadership philosophy is, sort of as a whole, and then maybe some examples of both good and not as ideal leadership that helped to shape it. [00:19:28] Dave Rosa: Yeah. So, I mean, for me, you know, the, the people that I've always looked at that I think are great leaders are, are those people that can communicate a vision and, and really instill a passion to inspire others in the company to have the same sort of passion to achieve this, this overall vision or this overall strategy. And, you know, I, you know, I-- there, there have been clearly people that I've worked for in my life that I've said, "Gosh you know, they, they really were inspirational to me to be better," not just I would say as a leader, but just more effective overall. And, you know, I, I, you know, I, I-- when I look at my own areas that when I think about leadership and what I can do to, to be more effective, you know, I some of the areas that I've personally looked at i- are things that can make the company more efficient. And artificial intelligence is probably the one that gets, you know, the most attention today. And, and I'm looking to using it, and took a course in this actually to, to really become more efficient and help the company be more efficient in, in developing these technologies and getting them to market as, as quickly as possible. And, and I think, you know, for myself, I'm, I'm very fortunate to be surrounded by a board of directors that I look at that I think have excellent leadership qualities, and it's, it's really, you know, meeting with them on a... and, and just talking to them on a fairly regular basis, picking their mind to see how they would handle things because, you know, I'm, I'm really the, the product of stealing ideas from other people that, that I think you know, have worked well and led to the success of companies and people that they've led. So it's, it's not necessarily taking a course on leadership, but it's surrounding yourself with people that have been successful in leading groups and, you know, getting ideas from them on how to be more efficient, whether it's, you know, taking classes you know, in, in things like AI or, or just, you know, learning from their own success as to how to inspire people to, you know, to really finish the goal for whatever that goal is. [00:21:58] Lindsey Dinneen: Yeah. Yeah, and speaking of inspiring people, how do you as a leader intentionally help shape the company culture that you feel is best for, for people to thrive in? [00:22:13] Dave Rosa: Yeah. So I've, I've always been of the mindset that companies that perform the best utilize ideas that others on the team have. So there, there are, I, I'll give you a great example. I-I find that people that come from big companies have more of a mindset of execution, meaning, "So whatever the boss tells me to do, I do and I'm, I'm not gonna challenge them." So it's, it's one more of, "I, I find out what I need to do and, and and I execute that." You know, in, in our company, one of the things I try to foster is that it's okay to have a, a different opinion. We're all here, you know, trying to be successful, and none of us have all the answers. Now, there's gonna be times when we as a, a team just can't agree, and when those times occur, then, you know, the, the CEO is going to have to make the final decision because that's in my mind, that's, that's really one of the roles of the CEO. But I can tell you, in our company and in other companies I've been in, a lot of the, the great ideas on what to do, you know, have really come from others. They haven't, they haven't come from me. I'm-- I may be setting the overall vision, but sometimes, you know, you, you take a small detour because someone in the group who wasn't afraid to speak up, you know, has an idea or a thought that you know, makes the, the outcome more successful, whether it's shortening the time or coming up with a different idea, a different concept. I constantly try to hi- hire people that have skill sets that I don't have. So for example, I recently, within the last two months hired a guy that had great experience in the pharma space and really how to navigate that space and understands the, the therapies that are out there. And in a very short period of time you know, I realized, "Gosh, this guy, you know, knows so much more than I know and I'm gonna learn a lot from him." So I think it's, it's, it's really empowering the people that you hire, you know, to express what their thoughts and their ideas are because I don't care what CEO you're talking about, none of us, you know, have all the answers. [00:24:33] Lindsey Dinneen: Yes. And recognizing that is, is definitely, I think, key. I think a lot of the leaders that I've been talking to recently talk about exactly what you've mentioned. It's, it's recognizing that y- you know, you, you, you do have your blind spots or your just, your areas of weaknesses, and that's okay 'cause we all do, right? But as long as you're willing to say, you know, "Okay, this might not be my area, but I trust the person whose area I know it is," then, then that's just such a great way to, to handle that and empower the next generation of leaders. So yeah, I love that that's your approach. [00:25:10] Dave Rosa: I also, you know, I, one other area that I think is also critical, and it goes back to what I said about individuals that I've met in larger companies, and I experienced this when I was in a larger company as well. You know, the focus becomes not making a mistake. And and, and it's because you know, the, these employees don't wanna make a mistake that's going to cost them their career in that company. So the safest thing to do is to do what your supervisor tells you to do, as opposed to take a chance and, you know, offer a different idea or a different concept. It's seen as risky and it's because there's this fear of making a mistake. I think it's smaller companies, especially in companies that I've run, you know, my, my philosophy is it's okay to make a mistake, but let's not make the same mistake more than once. I mean, they're, they're there to learn from. So let, let's, let's be smarter the, the second time, you know, because of that experience. But if people are afraid to make mistakes, you'll, you know, you're, you're never gonna get different ideas or different concepts you know, out, out, out amongst the group because of the fear of making a mistake. [00:26:26] Lindsey Dinneen: Mm-hmm. Right. Yeah, absolutely. Providing that, that opportunity and I, I know it's a bit of a cliche, but the, the idea of a safe environment at least to present those ideas and potentially counter opinions, and that's where creativity thrives is when you can iterate and bounce ideas off each other and, and come up with something that's, you know, you couldn't have done by yourself. Yeah, I love that approach. [00:26:50] Dave Rosa: Yeah. [00:26:51] Lindsey Dinneen: Yeah, so okay. This is, this is marvelous. I really appreciate all of this so far. But I'm gonna pivot the conversation a little bit just for fun. So imagine that you were to be offered a million dollars to teach a master class on anything you want. It could be within your industry, but it doesn't have to be. What would you choose to teach? [00:27:13] Dave Rosa: Yeah, this this doesn't fall under maybe necessarily, you know, a a class that you would see in a, a normal curriculum. But, you know, I-- it's, it's something that I've tried to talk to my own children about, and that's teaching them about being thankful for what they have and also, you know, giving back to others that are less fortunate. I-- you know, there's a saying that, that "comparison i- is the thief of joy." You know, the-- I, I think the human race in itself just has a way of always dwelling on, like, what we don't have as opposed to being, you know, thankful to God for all that we do have. And I, and I, I, you know, I, I really think that o- one of the things that I've tried to instill in, in, you know, my, my children, and now they're all grown, is you gotta be grateful for what, what you have, but you gotta find ways to find common ground with people and, and be sure to give back to others that, you know, haven't been as fortunate as you. I, I think that's, you know, what this world should be more focused on than, you know, all, all you hear about today is what we don't agree with and why this side or that political party, you know, is ruining the world. I think if we all focused a lot more of our energy on helping others you know, the, the world would be and this'll sound cliché, a much better place to live in. So if I could teach a course on instilling thankfulness and and the importance of helping others, that's what I would do [00:28:49] Lindsey Dinneen: Yeah. No, that I couldn't agree more. Gratitude and giving back are, are key and, and the world needs more of it, so I love that idea of a masterclass for sure. And how do you wish to be remembered after you leave this world? [00:29:06] Dave Rosa: Yeah, it's-- it kind of goes back to, you know, what my dad said to me, and that was you know, as, as a, a youngster and, and that is, you know, my, my passion and interest to really help others. Yeah, that sums it up the best. [00:29:23] Lindsey Dinneen: Yeah, absolutely. Okay, and final question: What is one thing that makes you smile every time you see or think about it? [00:29:33] Dave Rosa: I, I would say you know, there, there are people that will doubt you and put you down in your career and tell you why, you know, you'll never do this or you'll never do that. And I can honestly say I never thought, you know, I would ever stand in Nasdaq, you know, on Wall Street and take a company public. And, you know, the, the one thing I, I do kind of cherish is I've been able to do this twice, but the first time I remember standing on the stage before the activity started at Nasdaq and one of the people in the company said to me, they said like, "You know, you just had this smile, you know, on your face. You know, it looked like you were thinking of something." And I said, "Yeah, you know, I, I was thinking about all those times that people told me that, you know, I, you know, I would never be successful in my career," and you can define success in different ways, but it, it kind of made me feel good. It was the first time I think I really felt, you know, proud of myself that, "Wow, you know, I'm, I'm one of a very small percentage of people that have been fortunate enough to, to actually you know, take a company public." So, it always makes me smile. [00:30:52] Lindsey Dinneen: Yeah. Yeah, absolutely. Great answer, and that, that's a really cool moment to reflect back on. Well, Dave, this has been a great conversation. I so appreciate your willingness to, to talk with me today, but also to share about the, the incredible work that your company is doing and your heart for helping people from the very beginning of your childhood, and obviously a huge passion of yours throughout your life. And we are so honored to be making a donation on your behalf as a thank you for your time today to Opportunity International, which works to end global poverty by creating and sustaining jobs while also providing small business loans, savings, insurance, and training to more than 14 million people in the developing world. So thank you so much for choosing that organization to support, and thank you for everything that you're doing to change lives for a better world. [00:31:47] Dave Rosa: Well, thanks for having me on the show as well. [00:31:49] Lindsey Dinneen: Of course. [00:31:51] Dan Purvis: The Leading Difference is brought to you by Velentium Medical. Velentium Medical is a full service CDMO, serving medtech clients worldwide to securely design, manufacture, and test class two and class three medical devices. Velentium Medical's four units include research and development-- pairing electronic and mechanical design, embedded firmware, mobile app development, and cloud systems with the human factor studies and systems engineering necessary to streamline medical device regulatory approval; contract manufacturing-- building medical products at the prototype, clinical, and commercial levels in the US, as well as in low cost regions in 1345 certified and FDA registered Class VII clean rooms; cybersecurity-- generating the 12 cybersecurity design artifacts required for FDA submission; and automated test systems, assuring that every device produced is exactly the same as the device that was approved. Visit VelentiumMedical.com to explore how we can work together to change lives for a better world.

In our last episode, we featured a wearable device that uses gentle vibrations to help people manage Parkinson's symptoms and reduce anxiety. If you haven't listened yet, I encourage you to do so. It's a fascinating conversation about how something as simple as a vibrating wristband—BeechBand—may influence the brain in ways that help ease anxiety and tremors. Best of all, it's easy to use and fully refundable if it doesn't work for you in 100 days.. This episode also explores wearable technology, but with a very different purpose—one that could transform how we manage Parkinson's and partner with our healthcare teams. StrivePD, developed by Rune Labs, is an app that pairs with your Apple Watch to track movement, heart rate, sleep, and other important health data. It then provides easy-to-understand reports that highlight trends over time, giving you a clearer picture of how your Parkinson's is changing between doctor visits. Imagine arriving at your next appointment with objective, actionable information instead of relying on memory alone. That kind of insight can lead to more informed conversations and better care decisions. And this is only the beginning of what's possible with StrivePD. I thoroughly enjoyed my conversation with Rune Labs CEO Amy Gordon Franzen and learning about the future of digital health for Parkinson's. I think you'll find it both informative and inspiring. https://www.strive.group/ https://www.runelabs.io/post/strivepd-empowering-parkinsons-patients-with-personalized-insights amy@runelabs.io  Thank you to our sponsor – Boston Scientific, the maker of Vercise Genus, a Deep Brain Stimulation or DBS system. To learn more about the latest treatment options for Parkinson's disease at https://DBSandMe.com/17branches   

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the latest scientific advancements, regulatory milestones, and strategic business maneuvers shaping the industry. One of the standout developments comes from Otsuka with their drug Voyxact, which has shown promising results in stabilizing kidney function decline in patients with immunoglobulin A nephropathy (IgAN). In a Phase 3 trial, patients exhibited kidney function comparable to that of healthy adults. IgAN is a challenging autoimmune condition often leading to end-stage renal disease. This advancement, leveraging a monoclonal antibody to target specific pathways, could mark a new era in managing this chronic kidney disease. In oncology, Jiangsu Alphamab Biopharmaceuticals has been making waves through strategic collaborations, securing deals worth $125 million upfront and potential milestone payments reaching over $2 billion. Their focus on developing antibody-drug conjugates (ADCs) using AI and machine learning underscores the promise of precision oncology. ADCs marry the targeting precision of antibodies with potent anti-cancer drugs, highlighting robust investment and confidence in these cutting-edge therapies. Merck & Co. continues to expand its financial outlook, driven by the success of its flagship drugs like Keytruda. This monoclonal antibody remains pivotal in cancer immunotherapy, while drugs like Winrevair and Lipfendra are broadening Merck's reach into cardiovascular health. This growth trajectory reflects a strategic push toward diversifying product lines and leveraging breakthrough therapies to maintain strong financial performance. Additionally, Merck's $10.8 billion acquisition of Prometheus Biosciences aims to expand their therapeutic portfolio with targeted biologics. Although mid-stage trials showed mixed results for their anti-TL1A antibody therapy, such acquisitions are pivotal in addressing unmet medical needs. On the regulatory side, Sanofi's MenQuadfi vaccine has achieved EU approval for use in infants as young as six weeks. This approval enhances preventive measures against invasive meningococcal disease in vulnerable populations, representing a significant public health advancement. In research methodologies, Sethera Therapeutics' collaboration with Receptor.AI is notable. By integrating AI-driven platforms for polymacrocyclic peptide discovery aimed at hard-to-drug targets, they're paving the way for overcoming traditional drug discovery challenges through computational tools. However, not all news is about progress. Jazz Pharmaceuticals faced a setback by withdrawing its label indication for Zepzelca after failing Phase 3 trials for small-cell lung cancer. This underscores the inherent risks in clinical development pathways. From a financial standpoint, BioNTech has adjusted its 2025 sales forecast downward due to waning global demand for COVID-19 vaccines—a reflection of the volatile vaccine markets post-pandemic peaks. Meanwhile, Pfizer's discontinuation of its Phase 2 GIPR antagonist for obesity illustrates strategic pivots within R&D pipelines as companies reassess priorities based on trial outcomes and market potential. Recent corporate strategies include Pfizer's ambitious cost-saving plan totaling $9.7 billion through 2029. Amid economic pressures and patent expirations looming on key products like Eliquis, Pfizer is optimizing operations to stay competitive. Speculation around a possible merger between Bristol Myers Squibb (BMS) and AstraZeneca has stirred interest. With both facing patent cliffs, this merger could rejuvenate portfolios—though the strategic benefits for AstraZeneca are still debated. On the technological front, advancements in cellular therapies promise to revolutionize medicine production at the cellular level, potentially enhancing patient outcomes through more personalized treatments. The regulatory landscape is also evolving. There's a growing call for streamlining Investigational New Drug applications under the FDA's Trialblazer initiative—crucial for accelerating clinical trials and bringing innovative therapies to market swiftly. Finally, initiatives such as Boston Scientific's restructuring efforts highlight challenges within the medical device sector as companies adapt to shifting market dynamics. Overall, these developments underscore an industry in motion where innovation and adaptation are key to navigating complex landscapes and advancing patient care globally. As we look ahead, these trends will likely continue shaping the future of pharmaceuticals and biotech in profound ways.Support the show

Paul Byrne asks what the Boston Scientific restructuring means for Cork, hears Garda advice on Bank Holiday weekend travel, chats to Vanessa Feltz on reinventing herself and why she loves Cork. And more... Hosted on Acast. See acast.com/privacy for more information.

Paul talks to Donnchadh Ó Laoghaire TD who has concerns about the restructuring announcement yesterday Hosted on Acast. See acast.com/privacy for more information.

Today we're talking about BeechBand, a wearable wellness device designed to support people living with neurological conditions, including Parkinson's disease. If you've spent any time in the Parkinson's community lately, you've probably heard the name. Carl Beech, the co-inventor and founder, seems to be everywhere sharing the story behind this innovative wearable. Friends of mine who have purchased a BeechBand rave about the results. Carl regularly appears in my Instagram feed, and when I attended the World Parkinson's Congress (WPC) in May, his booth was consistently packed with people eager to learn more. It's clear that the word is getting out, and BeechBand appears to be gaining real momentum. I have to admit—I became a believer myself. In this episode, Carl shares the origins of BeechBand, the personal story that inspired its creation, and how the device is designed to help people with Parkinson's. Listen in to discover what makes this wearable so intriguing. You just might become a believer, too. https://www.beechband.com/pages/about Thank you to our sponsor – Boston Scientific, the maker of Vercise Genus, a Deep Brain Stimulation or DBS system. To learn more about the latest treatment options for Parkinson's disease at https://DBSandMe.com/17branches   

Recorded at EHRA 2026, this episode of The Lead features host Christopher Kowalewski, MD, in conversation with Christian Sohns, MD, and Pierre Jaïs, MD, about the journal article, 20 Years: Clinical Outcome After Pulmonary Vein Isolation in Patients With Symptomatic Drug-Refractory Paroxysmal Atrial Fibrillation. Together, they discuss the study's long-term clinical outcomes following pulmonary vein isolation in patients with symptomatic drug-refractory paroxysmal atrial fibrillation and explore the implications of two decades of follow-up.   Learning Objectives: Review the long-term clinical outcomes reported after pulmonary vein isolation in patients with symptomatic drug-refractory paroxysmal atrial fibrillation. Discuss the implications of 20-year follow-up data for the treatment of patients undergoing pulmonary vein isolation. Examine how long-term outcome data may inform clinical decision-making for catheter ablation in paroxysmal atrial fibrillation.   Host: Christopher Kowalewski, MD   Guests: Christian Sohns, MD and Pierre Jaïs, MD   Disclosures: C. Kowalewski No relevant disclosures   C. Sohns No relevant disclosures   P. Jaïs Ownership/Partnership/Prinicipal: inHEART Honoraria/Speaking/Consulting Fee: Biosense Webster, Inc., Boston Scientific, Medtronic

For some reason, I've always been fascinated by grief and the grieving process. It seems to be everywhere—in the TV shows I watch, the podcasts I listen to, and the conversations I have with friends. Every one of us experiences grief, yet no two people grieve in exactly the same way. I've become curious about why that is and what we can learn from one another's experiences. That curiosity led me to attend a Support Group Leader session on grief at the World Parkinson Congress last May. One of the presenters was my friend, Karen McIntyre, who introduced an idea that really resonated with me: grief doesn't begin only when someone we love dies. For people living with Parkinson's, grief can occur every time they lose an ability that was once part of everyday life—driving a car, walking long distances, writing by hand, or even enjoying the smell of a favorite meal. What does that kind of grief look like? Is grieving the loss of an ability different from grieving the death of a loved one? Or do they share more similarities than we realize? To explore those questions, I invited Karen, who writes thoughtfully about grief on her Substack, to join me in interviewing an expert in grief and bereavement. Together, we discuss how grief affects all of us, why it takes so many different forms, and how people with Parkinson's and their care partners can better understand and navigate the losses that accompany the disease. This episode is truly for everyone because, at some point in our lives, we all grieve someone or something that has mattered deeply to us. https://clairebidwellsmith.com/ https://www.elegy.co/ https://substack.com/@inmyshoesmemoir Thank you to our sponsor – Boston Scientific, the maker of Vercise Genus, a Deep Brain Stimulation or DBS system. To learn more about the latest treatment options for Parkinson's disease at https://DBSandMe.com/17branches   

In this episode, Jeremiah Johnson, Global Lean Leader at Boston Scientific, joins Kirby to break down exactly why hard-won gains slowly disappear and what it takes to stop the backslide for good. Jeremiah brings a hard-earned perspective that goes far beyond the factory floor! ------------------------------ Unlock practical tools, training, and support to help your team improve. Manufacturers Alliance members get full access to our webinar library, digital courses, member pricing, and a statewide network of leaders who share what's working on the factory floor. Links: Attend a Community Group: https://www.mfrall.com/community/ Listen on Spotify: https://open.spotify.com/show/5orRRXkVgAkbAeUuCj1dP5 Listen on Apple: https://podcasts.apple.com/us/podcast/how-manufacturers-improve/id1677078610 Watch on YouTube: https://www.youtube.com/@UCfj2OPOknywMeVwzPJX7Ifw

In this episode of Medsider Radio, we sat down with Bob Paulson, President and CEO of Sonex Health. Sonex's UltraGuideCTR device is a minimally invasive technology that enables ultrasound-guided carpal tunnel release procedures to be performed outside the surgical suite using local anesthesia, expanding patient access and reducing the cost of care.Before joining Sonex, Bob led multiple venture-backed medical device companies through commercialization, including NxThera, acquired by Boston Scientific, Restore Medical, acquired by Medtronic, and VentureMed Group. Earlier in his career, he held senior leadership roles at Medtronic, Advanced Bionics, and Endocardial Solutions, which was acquired by St. Jude Medical.In this interview, Bob explains how to build a reimbursement strategy before your first clinical study, drive physician adoption when introducing a new care pathway, and raise capital aligned with value inflection points. Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Bob Paulson, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:19) - Bob's path from Medtronic to multiple medtech exits before joining Sonex (05:38) - Why 80% of eligible carpal tunnel patients avoid surgery — and how Sonex is changing that (11:11) - The reimbursement challenge that reshaped Sonex's clinical evidence strategy (19:07) - Reimbursement is a three-leg process: FDA, CPT, and payer coverage (22:07) - Reverse engineering your company from the exit you're trying to achieve (29:35) - How Sonex helped surgeons move carpal tunnel procedures out of the OR (39:06) - Sonex's "pitcher-catcher" approach to physician and patient adoption (41:59) - Bob's framework for choosing investors who can finance the entire journey, not just the next round

Recorded at EHRA 2026, this episode of The Lead features host Michael S. Lloyd, MD, FHRS, in conversation with Tina Baykaner, MD, MPH, and Kenneth Ellenbogen, MD, FHRS, about the journal article, Real-time smartphone alerts during atrial fibrillation episodes with implantable cardiac monitors and wearable devices: SMART-ALERT study. Together, they discuss the study findings and explore the use of real-time smartphone alerts in conjunction with implantable cardiac monitors and wearable devices during atrial fibrillation episodes. Learning Objectives Review the design and key findings of the SMART-ALERT study evaluating real-time smartphone alerts during atrial fibrillation episodes. Discuss the use of implantable cardiac monitors and wearable devices for real-time detection and notification of atrial fibrillation episodes. Explore the potential clinical implications of integrating smartphone alerts with cardiac monitoring technologies.   Host: Michael S. Lloyd, MD, FHRS   Guests: Tina Baykaner, MD, MPH Kenneth A. Ellenbogen, MD, FHRS   Disclosures: M. Lloyd ·      Honoraria/Speaking/Consulting Fee: Medtronic, Boston Scientific, Other   T. Baykaner ·      Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific ·      Research: NIH, Boston Scientific   K. Ellenbogen ·      Honoraria/Speaking/Consulting Fee: American College of Cardiology, Heart Rhythm Society, Boston Scientific, Medtronic, Inc., Abbott ·      Royalty Income: Wiley-Blackwell, Elsevier

Intimacy is one of the most important topics we can discuss, yet it's also one that I've hesitated to bring to this podcast. For many of us, it's still considered a taboo subject. But the reality is that intimacy and relationships are an important part of life for everyone—and they can become even more important, and sometimes more challenging, for people living with Parkinson's disease and their care partners. Since I'm certainly not the expert on this topic—and I'll admit it makes me a little uncomfortable—I've invited someone who is. Dr. Kelly Rees is a licensed sex therapist in private practice who has a remarkable ability to discuss intimacy in an open, approachable, and judgment-free way. In our conversation, she explains why nurturing intimacy is so important throughout the Parkinson's journey, offers practical insights for navigating the changes that can occur, and reminds us that connection comes in many forms. So, whether you're living with Parkinson's, supporting someone who is, or simply interested in strengthening your relationships, I think you'll find this conversation both informative and reassuring. Let's listen https://drkellyrees.com/ https://www.aasect.org/referral-directory Thank you to our sponsor – Boston Scientific, the maker of Vercise Genus, a Deep Brain Stimulation or DBS system. To learn more about the latest treatment options for Parkinson's disease at https://DBSandMe.com/17branches   

Recorded at EHRA 2026, this episode of The Lead features host Michael S. Lloyd, MD, FHRS, in conversation with Tina Baykaner, MD, MPH, and Prashanthan Sanders, MBBS, PhD, FHRS, about the journal article, Atrial Mechanical Contraction Predicts Cerebrovascular Risk in Patients With Transthyretin Amyloid Cardiomyopathy and Sinus Rhythm. Together, they discuss the study findings and explore the relationship between atrial mechanical contraction and cerebrovascular risk in patients with transthyretin amyloid cardiomyopathy who are in sinus rhythm.   Learning Objectives: Review the key findings of the study examining atrial mechanical contraction and cerebrovascular risk in patients with transthyretin amyloid cardiomyopathy and sinus rhythm. Discuss the association between atrial mechanical contraction and cerebrovascular risk in this patient population. Explore the potential clinical implications of assessing atrial mechanical function in patients with transthyretin amyloid cardiomyopathy.   Host: Michael S. Lloyd, MD, FHRS   Guests: Tina Baykaner, MD, MPH Prashanthan Sanders, MBBS, PhD, FHRS   Disclosures: M. Lloyd Honoraria/Speaking/Consulting Fee: Medtronic, Boston Scientific, Other   T. Baykaner Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific Research: NIH, Boston Scientific   P. Sanders Honoraria/Speaking/Consulting Fee: Boston Scientific, Abbott Medical Other Financial Relationships: Medtronic PLC, Pacemate, CathRx Research: Abbott, Becton Dickinson, Calyan Technologies, Ceryx Medical, Biosense Webster, CathRx, HelloAlfred, Medtronic, Inc., Abbott Medical

I have told this story many times. After my diagnosis, my doctor wanted me to learn the "Big and Loud" program or LSVP. The physical therapist at the outpatient clinic saved my life. He told me I was going to live a long life and how to exercise Big. He told me to do something for my brain like play Mahjong.  I followed his directions. I go to physical therapy every year to continue to work on balance, posture and gait. I think a good PT is a key member of your medical team. Physical therapy is one of the most powerful tools available for living well with Parkinson's disease, and in this episode, Dr. Jennie Allex explains why movement is truly medicine. As a board-certified neurologic physical therapist and Parkinson's specialist, Jennie shares how targeted exercise can help people maintain mobility, improve balance, reduce fall risk, and preserve independence throughout every stage of the disease. In this episode, we are focused on one issue which is very important to address – balance. It turns out there is a lot going on in your brain and body to keep you upright. Jennie discusses how Parkinson's affects the three systems that work together in order to prevent falls.  She emphasizes how important it is to get an assessment from a qualified PT so you get the best treatment to improve your balance. The conversation explores practical strategies for balance while highlighting the importance of consistent exercise between therapy visits. Jennie explains how specialized Parkinson's programs, including evidence-based approaches such as PWR!Moves® and other Parkinson's-specific interventions, help retrain movement and build confidence. Whether you're newly diagnosed, have been living with Parkinson's for years, or care for someone with the disease, this episode provides practical, encouraging guidance on how physical therapy can help you move better, stay stronger, and continue living to the fullest.  https://www.dailydosepd.com/ https://theparkinsonsfitnessproject.com/ Thank you to our sponsor – Boston Scientific, the maker of Vercise Genus, a Deep Brain Stimulation or DBS system. To learn more about the latest treatment options for Parkinson's disease at https://DBSandMe.com/17branches   

In der heutigen Folge sprechen die Finanzjournalisten Nando Sommerfeldt und Holger Zschäpitz über den Circle-Schock, die Abivax-Erleichterung und Ernüchterndes von Nike. Außerdem geht es um Siemens Energy, Citigroup, Siemens, Bank of America, Abivax, SMA Solar, Jefferies, Circle, Visa, BlackRock, Alphabet, Coinbase, Cognizant, Intuit, Charter Communications, Boston Scientific, Oracle, Trimble, Leidos, UBS, OHB, iShares MSCI World Momentum Factor Advanced ETF (WKN: A3CUJS), iShares Edge MSCI World Quality Factor ETF (WKN: A12ATE), Vanguard FTSE All-World High Dividend Yield ETF (WKN: A1T8FV), iShares Edge MSCI World Minimum Volatility ETF (WKN: A1J781). Und hier der Podcast-Link zur Cash-Burners Lilium-Story: https://open.spotify.com/episode/0aFq46uMdsSDB7gRA1IXri?si=E66fBk32QEKoKAmgQRSp4g&nd=1&dlsi=e4be74d32e4148ff Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und – ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

How do you safely combine locoregional and systemic therapies to treat hepatocellular carcinoma (HCC) when traditional guidelines suggest your hands are tied? In this episode of the 2026 HCC Creator Weekend™, medical oncologist Dr. Lingling Du (Ochsner Health) and interventional radiologist Dr. Beau Toskich (Mayo Clinic Florida) join Dr. Tyler Sandow to break down patient selection, timing strategies, and the practical application of clinical trial outcomes when integrating Y90 radioembolization and immunotherapy in HCC management. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Sirtex and Boston Scientific. --- Timestamps 00:00 - Introduction01:48 - Two HCC Cases03:31 - Disease Progression on Combination Therapy07:05 - Alternatives After Immunotherapy Failure09:09 - Salvage with Ablative Y9013:41 - Mechanism of Immunotherapy15:43 - EMERALD-1 and LEAP-01220:52 - Adverse Events with Combination Therapy27:21 - Treatment Timing and Sequencing28:48 - Case: Borderline BCLC B33:48 - Case: BCLC C with Portal Vein Thrombus37:06 - Raising the Survival Tail40:11 - Final Thoughts and Closing Remarks --- More about this episode The physicians highlight how selective local treatment can achieve complete responses and salvage cases with aggressive disease. They emphasize that treatment based on anatomical and biological phenotype may yield better results than strictly adhering to rigid staging categories, while acknowledging the challenges of managing microscopic disease and unpredictable long-term tumor behavior. Dr. Du and Dr. Toskich also note that selecting the right combination regimens requires balancing aggressive tumor kinetics against the patient's baseline liver function, pointing out that well-tolerated regimens like STRIDE are often easier to pair with Y90 than checkpoint or VEGFR inhibitors that alter tumor blood flow. While recent TACE-immunotherapy trials (EMERALD-1 and LEAP-012) may be confounded by patient heterogeneity, the physicians observe that a distinct subset of patients achieves durable, long-term remission, effectively raising the survival tail for an otherwise incurable population. Ultimately, they conclude that cross-specialty education and leaning into the expert intuition of a multidisciplinary team are essential for securing the best outcomes for patients with intermediate and advanced HCC. --- Resources Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (HIMALAYA)https://clinicaltrials.gov/study/NCT03298451 A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave150)https://clinicaltrials.gov/study/NCT03434379 Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trialhttps://doi.org/10.1016/S0140-6736(25)00403-9 Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 studyhttps://doi.org/10.1016/S0140-6736(24)02551-0 Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 studyhttps://doi.org/10.1016/S0140-6736(24)02575-3 --- BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

This episode covers: Cardiology This Week: A concise summary of recent studies Host: Emer Joyce Guests: Yasmina Bououdina, JP Carpenter, Milton Packer, Lorenz Raeber Want to watch that episode? Go to: https://esc365.escardio.org/event/2558 Want to watch that extended interview on PCI guidance by intracoronary imaging, go to: https://esc365.escardio.org/event/2558?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Milton Packer has declared to have potential conflicts of interest to report: 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Daiichi Sankyo, Imara, Lilly, Medtronic, Moderna, Novartis, NovoNordisk, Pharmacocosmos, Regeneron, Roche, Salamandra. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Lorenz Raeber has declared to have potential conflicts of interest to report: consultation/speaker fees from Abbott, Boston Scientific, Occlutech, and research grants to the institution by Abbott, Heartflow, Novo Nordisk and Heartflow. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guest: Lorenz Raeber Want to watch that extended interview on https://esc365.escardio.org/event/2558?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2558   Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Lorenz Raeber has declared to have potential conflicts of interest to report: consultation/speaker fees from Abbott, Boston Scientific, Occlutech, and research grants to the institution by Abbott, Heartflow, Novo Nordisk and Heartflow. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

What if the reason your best ideas keep falling flat has nothing to do with the quality of the idea?In this episode, Michael Reddington sits down with John Bates, a globally recognized leadership and executive communications coach who has worked with organizations including NASA, Intuit, and Johnson and Johnson. John has delivered multiple TED Talks, coached executives and leaders on every continent, and built a career around one core conviction: communication is not logical. It is biological.This conversation will fundamentally change how you think about every high-stakes conversation you walk into. John breaks down why the ancient part of your brain makes decisions before your logical brain even gets a vote, why trying to establish your credibility usually destroys it, and why the most powerful thing a speaker can do is stop talking about themselves.John unpacks the neuroscience behind why people say yes, yes, yes and then no, how to build emotional credibility before you say a single persuasive word, and the difference between vulnerability that connects and vulnerability that costs you. If you lead people, sell ideas, or speak in front of any audience at all, this episode will give you a new framework for what it actually means to land your message where it counts.What You'll Learn in This EpisodeWhy communication is biological and why logic alone will almost never win a high-stakes conversationHow the paleomammalian brain makes decisions before the logical brain even registers themWhy the yes, yes, yes, no pattern in sales and negotiations is not a lie but a missing emotional connectionWhat emotional credibility is, why it needs to come first, and how to establish it fastHow insightful vulnerability builds trust faster than any credential or accomplishmentWhy your credibility is already established before you walk into the room and trying to prove it only hurts youThe difference between curating for your audience versus dumping everything you know on themWhy saying "I told you so" is proof you failed to communicate, not proof you were rightHow to reframe public speaking anxiety by shifting your attention from yourself to the people you are servingWhy the best ideas, candidates, and products often lose because communication broke down, not because they were wrongChapters(00:00) Why Communication Is Biological, Not Logical(04:24) How the Paleomammalian Brain Makes Decisions Before You Do(08:08) The Yes Yes Yes No Problem and What It Really Means(13:25) What Emotional Credibility Is and Why It Has to Come First(16:59) Origin Stories and the Power of Insightful Vulnerability(22:06) "Don't Insult the Listening" and the Lesson of Trusting Your Audience(26:56) Why Communication Is a Function of Leadership(28:33) Taking Responsibility for What People Hear, Not Just What You Say(33:05) How to Make the Complicated Simple by Curating, Not Dumping(41:37) How to Beat Public Speaking Anxiety by Serving Instead of PerformingAbout the GuestJohn Bates is an executive leadership communications coach, keynote speaker, and entrepreneur who has spent over 15 years helping leaders, teams, and organizations communicate in ways that actually move people. His clients include NASA, Intuit, Johnson and Johnson, Boston Scientific, and Accenture. He has delivered multiple TED Talks, been featured in media around the world, and built a global practice around the idea that great communication is not about saying the right things. It is about making sure the right things land. John coaches one on one, works with small and large teams, and produces free training content through his newsletter and website.Links and ResourcesJohnBates.com - https://www.johnbates.comExecutiveSpeakingSuccess.com - https://www.executivespeakingsuccess.comJohn Bates | LinkedIn - https://www.linkedin.com/in/johnbatesSponsor Links:InQuasive: http://www.inquasive.com/Humintell: Body Language - Reading People - HumintellEnter Code INQUASIVE25 for 25% discount on your online training purchase.International Association of Interviewers: Home (certifiedinterviewer.com)Podcast Production Services by EveryWord Media

What do you do when Y-90 doesn't deliver the results you expected? In this episode of the 2026 HCC Creator Weekend™, host Dr. Tyler Sandow is joined by Drs. Beau Toskich and Juan Gimenez to discuss the technical challenges and troubleshooting strategies that can make or break a Y-90 radioembolization case. Together, they explore innovative approaches like the PREDATr technique, share tips for reducing complications, and offer guidance on optimizing outcomes for patients with complex liver tumors. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Sirtex and Boston Scientific. --- Timestamps 00:00 - Introduction04:24 - Treatment Nonresponse Troubleshooting06:12 - Navigating Y90 Through Replaced Arteries09:09 - Mitigating Vasospasm in Embolization13:31 - What is ‘PREDATr'?21:12 - Dual Balloon Microcatheter System23:37 - Gelfoam Techniques and Application26:06 - Embolization Agents Preferences36:16 - Concerns with Cystic Artery Treatment and Biliary Stents42:15 - Prophylactic Antibiotics 44:29 - Utilizing High Lung Shunts49:28 - Wrap Up and Credits --- More about this episode The conversation begins with case-based examples of HCC radioembolization, focusing on how to assess treatment response and troubleshoot nonresponsive cases. They discuss how to interpret SPECT findings, identify missed tumor supply with cone-beam CT, and overcome obstacles such as vasospasm, extrahepatic feeders, and challenging arterial anatomy. They introduce the PREDATr technique (proximal radioembolization enabled by distal angiozone truncation) and explain how tools like gelfoam, balloons, and retrievable coils can preserve healthy liver tissue and improve microsphere delivery. The episode also addresses managing biliary stents, using antibiotic prophylaxis, and strategies for handling high lung shunts, making it a practical resource for anyone navigating the complexities of Y-90 treatment. --- BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Durante anos, a prevenção de AVC na fibrilação atrial seguiu uma lógica relativamente simples: identificar o risco tromboembólico e prescrever anticoagulação.Mas a prática clínica mostrou que a equação é mais complexa.Sangramentos maiores, hemorragias intracranianas, baixa adesão, fragilidade, quedas recorrentes e limitações socioeconômicas frequentemente colocam médicos e pacientes diante de decisões difíceis.No Ep. 228 do DozeCast, os hosts Diandro Motta e Victor Bemfica, recebem a cardiologista Dra. Brunna Pileggi e a neurologista Dra. Gisele Sampaio para analisar em profundidade o Champion-AF, estudo que avalia o fechamento percutâneo do apêndice atrial esquerdo (LAAC) com dispositivo Watchman como alternativa à anticoagulação oral direta em pacientes com fibrilação atrial.A grande provocação do estudo é simples: devemos continuar reservando o fechamento do apêndice atrial apenas para situações extremas ou chegou o momento de antecipar essa decisão?O que você vai aprender:

In this episode of The Lead, host Christopher Kowalewski, MD, is joined by John M. Mandrola, MD, and Nassir F. Marrouche, MD, FHRS, to discuss the journal article, The Association Between Atrial Fibrillation Burden and Quality of Life: A Substudy of the SHAM-PVI Trial. Together, they explore the relationship between atrial fibrillation burden and quality of life, reviewing findings from this substudy of the SHAM-PVI Trial and discussing their relevance to patient-centered outcomes. Learning Objectives Review the key findings from the SHAM-PVI Trial substudy examining the association between atrial fibrillation burden and quality of life. Discuss the relationship between atrial fibrillation burden and patient-reported quality-of-life outcomes. Explore the implications of assessing both arrhythmia burden and quality of life when evaluating treatment outcomes in atrial fibrillation.   Host: Christopher Kowalewski, MD Guests: John M. Mandrola, MD and Nassir F. Marrouche, MD, FHRS   Disclosures: Christopher Kowalewski, MD No relevant disclosures   John M. Mandrola, MD No relevant disclosures   Nassir F. Marrouche, MD, FHRS •       Honoraria/Speaking/Consulting Fee/Speaker's Bureau: Biosense Webster, Inc., Boston Scientific, AtriCure, Inc., Abbott, Sanofi •       Research: Abbott, Biosense Webster, Inc., Medtronic, Siemens, General Electric, Boston Scientific, Sanofi, Samsung

MedTech innovation succeeds when bold ideas are matched with disciplined execution, strong teams, and a clear purpose. In this episode, James Corbett, transformational MedTech CEO and Board Advisor, joins Saul to share the leadership lessons, operating principles, and industry changes that have shaped his decades-long career. Drawing on experience leading companies including Boston Scientific, ev3, Alphatec Spine, CathWorks, and AVITA Medical, Jim explains why people and purpose are the foundation of lasting success in healthcare. He discusses the future of MedTech, including the creation of new clinical categories, the importance of operational excellence, and the growing role of AI in leadership and business transformation. Jim also shares why many organizations are underutilizing AI, how his AI command center captures decades of operating knowledge, and why great people remain the ultimate competitive advantage. Tune in and learn how purpose-driven leadership, operational discipline, and AI-enabled execution can help shape the next generation of MedTech innovation! Resources: Connect with and follow James Corbett on LinkedIn. Explore Jim Corbett AI!

Der Börsengang von SpaceX ist kein normales IPO, sondern ein Stresstest für Anleger, ETFs und Indexanbieter. Deshalb dominiert er den ersten Teil unserer Q&A-Reihe: Tobias Kramer beantwortet eure Fragen zu SpaceX, Starlink, American Tower, DAX und FAZ-Index, Gesundheitsaktien und Depot-Transparenz – nüchtern, mit Zahlen, ohne Hype. SpaceX kommt zu 135 bis 162 Dollar je Aktie an die Börse, das entspricht einer Bewertung von 1,8 bis 2,1 Billionen US-Dollar. Neue Class-A-Aktionäre halten danach zusammen gerade einmal 11,5 Prozent der Stimmrechte, während Elon Musk über seine Class-B-Aktien mit zehnfachem Stimmrecht rund 85 Prozent der Stimmen kontrolliert. Tobias rechnet einen bewusst optimistischen Bull Case durch (400 Mrd. Umsatz und 30 Prozent Nettomarge bis 2033) – und landet selbst dann bei einer unbequemen Antwort auf die Frage: Wie viel Zukunft ist hier schon bezahlt? Die Themen im Überblick: ▪️ Starlink Mobile als Angriff auf Deutsche Telekom, T-Mobile US und den globalen Mobilfunkmarkt – Chance, Schwachstelle und Frequenz-Politik ▪️ Nasdaq 100 vs. S&P 500: Warum die Fast-Track-Aufnahme von SpaceX Kritik verdient – und der S&P 500 mit seinen Regeln überzeugt ▪️ American Tower: Hat der Funkturm-REIT gegen Starlink noch eine Zukunft? ▪️ SpaceX shorten? Warum Tobias dringend davon abrät – Stichwort Lock-up-Fristen und Optionsprämien ▪️ DAX oder FAZ-Index: Welcher deutsche Index gehört ins Depot? ▪️ Gesundheitsaktien (Abbott, Medtronic, Pfizer, Boston Scientific): Übersehener Sektor oder Value-Falle? ▪️ Depot-Einblick: Der Link zur Google-Sheet-Übersicht steht in den Timestamps Unterm Strich eine klare Absage an Bewertungsromantik: Große Visionen reichen nicht, wenn Anleger heute schon den Gewinn von übermorgen bezahlen. Schreibt in die Kommentare, wie ihr den SpaceX-Case rechnet: 2 Billionen gerechtfertigt, 60 Prozent Rückschlagpotenzial – oder seht ihr den Weg zu 10 Billionen? Und wenn ihr solche Q&A-Folgen wollt: Abonniert den Kanal und meldet euch für unseren Mail-Verteiler auf echtgeld.tv an – dort laufen Umfragen, Fragerunden und Verlosungen. Teil 2 mit den weiteren Fragen (u. a. Marvell Technology und LVMH) folgt in der nächsten Sendung.

In this episode of The Lead, host Christopher C. Cheung, MD, MPH, FHRS, is joined by Edward P. Gerstenfeld, MD, MS, FHRS, and Paul C. Zei, MD, PhD, FHRS, to discuss the journal article, A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablation versus Anti-Arrhythmic Drug Therapy as a First Line Treatment for Persistent Atrial Fibrillation (AVANT GUARD). Together, they review the study design and findings, examining pulsed field ablation and anti-arrhythmic drug therapy as first-line treatment approaches for patients with persistent atrial fibrillation. Learning Objectives Review the design and key findings of the AVANT GUARD study comparing pulsed field ablation with anti-arrhythmic drug therapy as first-line treatment for persistent atrial fibrillation. Discuss the potential role of pulsed field ablation as an initial treatment strategy for patients with persistent atrial fibrillation. Examine the comparative considerations of ablation-based and pharmacologic approaches in the management of persistent atrial fibrillation.   Podcast Contributors: Host: Christopher C Cheung, MD, MPH, FHRS       Guests: Edward P. Gerstenfeld, MD, MS, FHRS and Paul C Zei, MD, PhD, FHRS   Disclosures: Christopher C Cheung, MD, MPH, FHRS Honoraria/Speaking/Consulting Fee: Medtronic, Inc., Biotronik, Biosense Webster, Inc., Abbott Edward P. Gerstenfeld, MD, MS, FHRS Honoraria/Speaking/Consulting Fee: Medtronic, Inc., Biosense Webster, Inc., Abbott, Boston Scientific, Varian Medical Systems Other Non-Financial Relationships: Adagio Medical, Boston Scientific, Abbott Medical Research: Abbott Medical Officer, Trustee, Director, Committee Chair, or Other Fiduciary Role: American College of Cardiology Paul C Zei, MD, PhD, FHRS Honoraria/Speaking/Consulting Fee/Speaker's Bureau: Varian Medical Systems, Biosense Webster, Inc., Abbott, Boston Scientific, APT Medical Research: Biosense Webster, Inc.

How can targeted liver radiation unlock surgical or transplant options for tough hepatocellular carcinoma (HCC) cases? In this episode of BackTable 2026 HCC Creator Weekend™ host Dr. Kavi Krishnasamy is joined by interventional radiologists Dr. Beau Toskich and Dr. Chris Malone to explore how downstaging and radiation lobectomy with Y-90 are creating new surgical and transplant opportunities for patients with limited future liver remnants. They discuss Y-90's role as a “test of time” for tumor biology, strategies to prevent post-hepatectomy liver failure, and the ongoing challenge of recurrence even after R0 resection in cirrhotic livers. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Sirtex and Boston Scientific. --- Timestamps 00:00 - Introduction01:31 - Rad Lobectomy Goals and Case Discussion06:09 - Selective vs Lobar Dosing07:51 - PVE Versus Y9009:35 - Downstaging to Transplant13:03 - Patient Selection Factors19:22 - Radseg vs. Lobar Strategy22:12 - Percent Liver Treated Debate26:38 - Particle Density and Catheter Bias28:04 - Downstaging Evidence MERIT LT36:20 - Operating After Y9041:25 - Hypertrophy Timing and Readiness43:03 - Wrap Up --- More about this episode The discussion features a case of massive right-lobe HCC in a non-cirrhotic patient, with stepwise Y-90 dosing and selective retreatment leading to complete response and marked liver hypertrophy. The doctors compare radiation lobectomy with portal vein embolization (PVE), explore dosimetry advances from studies like DOSISPHERE and MERITS-LT, and stress the importance of careful mapping and patient selection. Additional topics include the pros and cons of different downstaging methods, functional imaging to assess risk, the impact of lab values and portal hypertension, and the practicalities of timing surgery after Y-90. --- Resources Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trialhttps://jnm.snmjournals.org/content/early/2024/01/10/jnumed.123.266211 Downstaging hepatocellular carcinoma before liver transplantation: A multicenter analysis of the "all-comers" protocol in the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortiumhttps://pubmed.ncbi.nlm.nih.gov/37532179/ --- BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Board of Regents of the University of Texas v. Boston Scientific Corp.

What does it really take to run a high-volume Y-90 program that is efficient, scalable, and patient-centered? In this episode of BackTable 2026 HCC Creator Weekend™, host Dr. Zach Berman is joined by Drs. Nima Kokabi and Kirema Garcia-Reyes to break down the systems, workflows, and strategies that drive successful radioembolization centers. The conversation focuses on overcoming referral and insurance delays, implementing multidisciplinary clinics, and using tools like single-session Y-90 and routine post-treatment dosimetry to reduce treatment times and improve outcomes. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Sirtex and Boston Scientific. --- Timestamps 00:00 - Introduction04:46 - Multidisciplinary Model on Radioembolization08:39 - Referral Pathways and Embolization Preferences13:18 - Y-90 Follow Up and Imaging15:51 - Procedure Preparation and Involvement18:00 - Dosimetry Planning and Software ROI22:59 - Analyzing Outcomes and Quality Control26:47 - Various Ways to Expedite Treatments34:04 - Wrap Up and Credits --- More about this episode The doctors discuss the importance of robust internal systems for patient selection, integration of dosimetry planning, and standardized follow-up protocols.They share insights on procedural workflows, including best practices for dosimetry ownership and equipment setup, and highlight the growing role of post-Y-90 dosimetry as both a quality control measure and a billable service. The episode also explores the order-map-treat paradigm, the impact of multidisciplinary tumor boards and clinics, and how single-session strategies are reshaping HCC care by cutting delays, reducing costs, and enhancing the patient experience. --- BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Most CEOs think their sales pipeline is healthy, but the real story is hiding in stalled and quietly lost deals. We unpack why processes always beat skills for predictability and how top sales teams are winning bigger in a tougher market. In this episode, Janice B Gordon sits down with Steve Gielda to reveal the pitfalls of sales assumptions and the strategic moves that accelerate revenue and increase deal velocity. What you'll learn: a) Why understanding your buyer's real metrics is the secret to beating lower-cost competitors b) The critical difference between stages and milestones in sales processes c) How assumptions, especially by experienced reps, kill deals Steve Gielda has spent 30 years at the forefront of global sales performance, co-founding Ignite Selling and helping world-class organisations like Boston Scientific, Siemens, and Mastercard drive faster, more strategic revenue growth. Timestamps: 00:00 Understanding buyer priorities and metrics 04:53 Understanding the buyer's perspective 08:42 Identifying and leveraging key stakeholders 13:30 Improving sales processes 16:27 Defining and leveraging stakeholders 19:00 Win-loss analysis findings 23:23 Engaging sales rep conversations 27:18 Strategic sales approach boosts revenue 31:36 AI tools for sales strategies 32:58 Defining product advocates   Connect with Steve LinkedIn: https://www.linkedin.com/in/sgielda/   Connect with Janice Book Janice to speak at your next sales or leadership event: https://janicebgordon.com LinkedIn: https://www.linkedin.com/janice-b-gordon/ Instagram: https://www.instagram.com/janicebgordon Scale Your Sales Podcast: https://scaleyoursales.co.uk/podcast Enjoy the episode? Share your takeaway in the comments and leave a review on Apple Podcasts to help more leaders discover the show.

Great medtech innovations win because patients actually use them. In this episode, Ken Nelson, Partner and Founder at Nelson Jennings Ventures, shares his journey from cardiac device sales at Boston Scientific to helping commercialize major players in cardiac monitoring, including iRhythm, BioTelemetry, and Bardy Diagnostics. He highlights how innovations such as wearable cardiac patches have transformed patient adoption and reshaped the monitoring market. Ken reflects on Medtech Innovator's impact in accelerating commercialization, partnerships, and investor readiness. He advises early-stage companies to leverage accelerators and industry events like Life Science Intelligence to strengthen their path to market and fundraising success. Tune in to hear how decades of experience in cardiac monitoring and startup scaling translate into practical advice for founders navigating commercialization and growth! Resources: Connect with and follow Ken Nelson on LinkedIn.

Send us Fan MailMeet Ash Seddeek, a globally recognized executive coach and change leadership advisor with over 15 years of experience helping leaders drive transformation through compelling communication and strategic influence. Ash has coached senior teams at Cisco, Uber, Google, Boston Scientific, San Francisco International Airport and Doosan Bobcat. A former leader at Deloitte, Oracle, and Cisco, Ash blends deep expertise in executive presence, strategic facilitation, and change sponsorship. Ash is also an Amazon bestselling author and creator of leadership frameworks such as Chief Excitement Officers (CExOs) and Exponential Value Moments (EVMs) through which he equips leaders to lead with clarity, align stakeholders, and inspire action. Ash is a two-time Fulbright Scholar, linguist, AI fintech inventor, and entrepreneur. Ash is currently also working on a passionate AI startup Intelligent Context AI. Hit play for the lowdown! [4:26s] Fulbright Scholar to Leadership Communication Coach[6:48s] The Top 1 % for Sales Leadership [9:36s] Strategic Communication in Leadership [16:10s] On his book ‘Meaning: How Leaders Create Meaning and Clarity During Times of Crisis and Opportunity' [19:33s] What makes a great coachee[31:48s] On AI in the world of coaching[41:46s] On his Intelligence Context AI launch plansRWL Read: ‘Meaning: How Leaders Create Meaning and Clarity During Times of Crisis and Opportunity' by Ash Sedeek and Leslie Rubin; 'The Path of Least Resistance' by Robert FritzRWL Listen: Jim Rohn Motivation Connect with Ash on LinkedIn or email him at ash@executivegreatness.com Connect with Vinay on LinkedIn What did you think about this episode? What would you like to hear more about? Or simply, write in and say hello! podcast@c2cod.comSubscribe to us on your favorite platforms – Google Podcasts, Apple Podcasts, Spotify, Overcast, Tune In Alexa, Amazon Music, Pandora, TuneIn + Alexa, Stitcher, Jio Saavn and more.  This podcast is sponsored by C2C-OD, your Organizational Development consulting partner ‘Bringing People and Strategy Together'. Follow @c2cod on Twitter, LinkedIn, Instagram, Facebook 

Can the right dosimetry approach turn palliative Y90 into a curative therapy? In this episode of the BackTable 2026 HCC Creator Weekend™, Interventional oncologists Dr. Riad Salem, Dr. Nima Kokabi, and Dr. Zach Berman examine modern Y90 dosimetry, from the decline of body-surface-area calculations to newer strategies that tailor treatment intensity to tumor burden, liver reserve, and clinical intent. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Sirtex and Boston Scientific. --- Timestamps 00:00 - Introduction03:16 - MIRD and Dosing Considerations06:20 - BSA Is Dead09:26 - Early Stage Segmentectomy13:04 - Sphere Density Questions18:12 - CPN as the Goal18:41 - BCLC B Multifocal Strategy22:56 - Radiation Lobectomy Explained25:49 - Surgery and Adhesions28:59 - Advanced PVT Patients30:22 - Dosisphere and Biomarkers34:29 - Wrap Up --- More about this episode The doctors discuss how to choose how much radiation treatment to give and why “activity” (what you order) is different from “dose” (what tissue receives). The episode goes on to compare one-area calculations with more nuanced methods that distinguish tumor from healthy tissue, and explains why advanced 3D planning is often simpler after treatment than before. The discussion also covers treatment goals for various clinical scenarios, such as when to aim for complete ablation versus palliation, managing radiation lobectomy, and tailoring therapy in cases with portal vein tumor thrombus. The episode concludes with insights on how imaging informs treatment intensity and how local and systemic therapies work together in the latest Y90 approaches. --- Resources Combination treatment with transarterial chemoembolization, radiotherapy, and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumor thrombosis: Final results of a prospective phase II trialhttps://pmc.ncbi.nlm.nih.gov/articles/PMC5581058/ A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET studyhttps://pubmed.ncbi.nlm.nih.gov/35394152/ Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinomahttps://pubmed.ncbi.nlm.nih.gov/27575820/ Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trialhttps://jnm.snmjournals.org/content/early/2024/01/10/jnumed.123.266211 --- BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

This late-breaking sub-analysis from the CHAMPION-AF trial evaluated outcomes of left atrial appendage closure (LAAC) with the WATCHMAN FLX device versus oral anticoagulation in patients with atrial fibrillation who had previously undergone catheter ablation. Investigators found that LAAC provided similar protection against stroke, cardiovascular death, and systemic embolism compared with non-vitamin K oral anticoagulants (NOACs), while significantly reducing non-procedural bleeding events, regardless of prior ablation status. These findings suggest LAAC may be a viable alternative to long-term anticoagulation in select post-ablation AF patients through a shared decision-making approach. Join Digital Education Committee member Sandeep A. Saha, MD, MS, FHRS and his colleagues Scott C. Brancato, MD, FHRS and Rakesh Gopinathannair, MBA, MD, FHRS for this late-breaking coverage from Heart Rhythm 2026 in Chicago!   Learning Objectives Review the rationale for left atrial appendage closure as an alternative to long-term oral anticoagulation in patients with atrial fibrillation following catheter ablation. Analyze the CHAMPION-AF sub-analysis outcomes comparing LAAC and NOAC therapy with respect to stroke prevention, cardiovascular outcomes, and bleeding risk. Discuss how these findings may influence patient selection and shared decision-making for stroke prevention strategies in post-ablation atrial fibrillation care.    Podcast Contributors Sandeep A. Saha, MD, MS, FHRS Scott C. Brancato, MD, FHRS Rakesh Gopinathannair, MBA, MD, FHRS    Host and Contributor Disclosure(s): S. Brancato Nothing to disclose. R. Gopinathannair Board/Advisory Committee Membership: Heart Rhythm Society, AltaThera Pharmaceuticals Honoraria/Speaking/Teaching/Consulting: Abbott, Johnson and Johnson, Boston Scientific, Sanofi S. Saha Board/Advisory Committee Membership: Medtronic Honoraria/Speaking/Teaching/Consulting: Medtronic 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry is currently navigating a pivotal era marked by a blend of scientific innovation, regulatory shifts, and intriguing clinical trial results. A key regulatory upheaval unfolds as the FDA faces leadership changes. The recent departures of key figures from both the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER) underscore a period of uncertainty. With former commissioner Marty Makary stepping down, concerns arise about how these changes might affect drug approvals and regulatory guidance at such a crucial time in the industry. Turning to clinical trials, Regeneron has experienced a setback as its lag-3 inhibitor failed to surpass Merck's Keytruda in phase 3 melanoma studies. This marks Regeneron's second significant late-stage failure within a year, prompting analysts to reassess its strategic direction in oncology. In parallel, Regeneron has inked a $2.3 billion agreement with Parabilis Medicines to develop an advanced antibody-drug conjugate (ADC)-like therapy. The goal is to enhance targeting capabilities by improving binding to complex target sites, which could revolutionize ADC technology. Similarly, BioMarin's substantial investment in Inozyme's enzyme replacement therapy faced hurdles after falling short on one of two primary endpoints in a phase 3 trial for a rare genetic disorder. Such outcomes highlight the inherent risks and high stakes involved in late-stage drug development. Yet, innovation continues to drive progress. Vincentage Pharma's oral GLP-1 agonist has demonstrated a promising mean weight loss of 12.4% over a year, positioning it as a competitor to Eli Lilly's Orforglipron in the burgeoning Chinese market. This reflects the global pursuit to harness GLP-1 receptor agonists in tackling metabolic disorders and obesity. Ipsen has made strides with its long-acting neurotoxin for aesthetic applications, advancing into phase 3 trials following encouraging phase 2 results that showed significant improvements in frown lines lasting up to 24 weeks post-treatment. This progress suggests robust competition against established players like Botox. Meanwhile, Merck and Kelun-Biotech have successfully completed a phase 3 trial with their trop2-directed ADC sacituzumab tirumotecan (SAC-TMT) for endometrial cancer, achieving primary endpoints and paving the way for further regulatory submissions. Such advancements emphasize ADC technology's growing importance in oncology therapeutics. Broad industry trends reflect strategic investments, exemplified by Boston Scientific's $1.5 billion investment in Mirus and an option to acquire its transcatheter aortic valve replacement system—highlighting continued interest in high-growth medtech sectors. In another notable development, Daiichi Sankyo and AstraZeneca have reached a milestone with their ADC Enhertu, securing dual FDA approvals for early breast cancer treatment. These approvals underscore Enhertu's potential to expand treatment options for patients at an early disease stage, potentially altering standard treatment protocols. On the regulatory front, AstraZeneca has secured FDA approval for baxdrostat—an aldosterone synthase inhibitor developed through its acquisition of CinCor Pharma—demonstrating strategic investment in innovative cardiovascular therapies aligned with ambitious revenue goals. However, challenges persist as demonstrated by Amgen's Tavneos being linked to fatalities across Japan and the U.S., raising significant concerns about data integrity and pharmacovigilance. In contrast, Revolution Medicines' RAS inhibitor doubled survival rates in phase 3 pancreatic cancer trials. This breakthrough positions Revolution as an emerging leader in oncology therapeutics amidst fierce competition from companies aiming to improve drug tolerability and extend survival benefits. These narratives paint a picture of an industry poised for transformation—balancing scientific breakthroughs against regulatory challenges and financial pressures. As therapeutic modalities evolve—from oral biologics to advanced ADCs—the sector is set on course for substantial impacts on patient care and drug development pipelines. In summary, the pharmaceutical and biotech industries' focus on advancing therapeutic options through scientific innovation while navigating complex regulatory landscapes underscores an ongoing commitment to addressing unmet medical needs through new drug classes and targeted therapies. These efforts highlight trends toward personalized medicine and precision oncology that are likely to shape future trajectories in these dynamic fields.Support the show

This week, we revisit our conversation with Rich Ferrari. Rich is a seasoned healthcare entrepreneur and investor with a track record of building and scaling medical device and biotech companies. He is a Co-Founder of De Novo Ventures, a premier life sciences venture firm that managed $650M, and has helped raise over $1B in capital while contributing to nearly $1.8B in successful acquisitions. Most recently, Rich served as CEO and Chairman of PQ Bypass, leading to its $350M acquisition by Endologix. He has also led and exited multiple companies, including Cardiovascular Imaging Systems (acquired by Boston Scientific) and CardioThoracic Systems (acquired by Guidant), where he drove one of the fastest IPOs in medtech history. A prolific founder, Rich has co-founded several successful ventures acquired by major players like Johnson & Johnson, Abbott, and Medtronic. He currently serves on multiple boards, including Tenon Medical (NASDAQ: TNON), HeartBeam, and Medlumics. Rich holds a BS from Ashland University and an MBA from the University of South Florida, and is a recipient of the Mallinckrodt Award for Excellence in Medicine.

A high-functioning HCC tumor board can turn complex transplant decisions into coordinated treatment plans that account for liver reserve, tumor biology, and evolving biomarkers. In this episode of the BackTable Podcast 2026 HCC Creator Weekend™, abdominal transplant surgeon Dr. Ari Cohen (Ochsner Health) and transplant hepatologist Dr. Neil Mehta (UCSF) join host Dr. Kavi Krishnasamy to map out strategies for effective multidisciplinary treatment and transplantation planning in HCC. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Sirtex and Boston Scientific. --- Timestamps 00:00 - Introduction00:51 - Starting a Tumor Board06:39 - Building Referral Streams09:03 - Academic and Community Practice Integration14:31 - Treatment Selection Criteria20:38 - Modern HCC Biomarkers25:24 - Role of ctDNA and Biopsy29:37 - Bridging Therapy on Transplant Waitlist32:34 - Downstaging Strategy and Risks39:25 - Final Thoughts and Closing Remarks --- More about this episode The physicians discuss what it takes to build a robust tumor board, from fostering hospital buy-in to engaging leaders across specialties and utilizing virtual formats for consistent participation. The conversation explores clinical decision-making, emphasizing the integration of AFP-L3 and DCP biomarkers alongside AFP to better understand tumor biology and predict post-transplant recurrence. Dr. Mehta and Dr. Cohen also share their patient selection criteria, discussing how bilirubin, liver disease etiology, and INR influence decisions. While radiographic guidance remains central to HCC management, they highlight the growing potential of reliable ctDNA analysis and other biomarkers. The specialists conclude by emphasizing that an integrated, communicative tumor board is the most effective way to navigate the nuances of liver reserve and HCC biology to achieve the best possible patient outcomes. --- Resources Sustained AFP-L3 or DCP expression is associated with progression risk and inferior outcomes in unresectable hepatocellular carcinoma.https://doi.org/10.1007/s10238-025-01877-8 --- BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Boston Scientific Corp. v. Stryker Corporation

Today we are going to describe and explain neuropathy. What is it? Why am I experience the symptoms? What causes the symptoms to come and go? Is it due to my Parkinson's disease or just old age? This is the second of three episodes in the "Dr. Ospina Explains" series. In this episode, we learn all about neuropathies. So, if you have or had or anticipate having any tingling, numbness, burning, weakness is your feet or elsewhere, this is the episode for you. https://www.apdaparkinson.org/article/peripheral-neuropathy-parkinsons-disease/ Thank you to our sponsor – Boston Scientific, the maker of Vercise Genus, a Deep Brain Stimulation or DBS system. To learn more about the latest treatment options for Parkinson's disease at https://DBSandMe.com/17branches   

Kat Hurd, executive coach and founder/CEO of Med Tech Collective, shares how nearly two decades in medical device sales and leadership, including at Boston Scientific and Saluda Medical, shaped her mission to help reps and leaders build influence, ownership, and long-term career momentum in complex, high-stakes environments. Kat explains why strong clinical partnership can elevate sales conversations into trusted-advisor relationships that impact outcomes, and outlines how she coaches individuals, trains teams, and supports go-to-market strategy. She also dives into the distinct challenges women face when navigating rooms where they're “the only,” the career accelerant of mentorship versus sponsorship, and practical ways to break into medtech by identifying gaps and learning the industry's language.    Guest links: https://kathurd.com/   Charity supported: Save the Children Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host & Editor: Lindsey Dinneen Producer: Velentium Medical   EPISODE TRANSCRIPT Episode 079 - Kat Hurd [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome back to another episode of The Leading Difference podcast. I'm your host Lindsey, and I am delighted to welcome today Kat Hurd. Kat is an executive coach and the founder of MedTech Collective, where she helps medical device sales reps and leaders build influence, ownership, and long-term career momentum in complex, high stakes environments. With nearly two decades of real world experience in medical device sales and leadership, including senior roles at Boston Scientific and Saluda Medical, Kat brings a rare blend of commercial rigor, strategic insight, and credibility earned in the field based in Arizona. Kat is a speaker, advisor and coach who believes that when sales reps and leaders learn to own their voice, their business and their influence, the ripple effects extend far beyond individual success, shaping teams, cultures, and the future of the industry itself. Kat, welcome. Thank you so much for being here today. I'm super excited to speak with you. [00:01:45] Kat Hurd: Thank you so much for having me, Lindsey. It is an honor. I always love these conversations. [00:01:49] Lindsey Dinneen: Excellent. Well, if you don't mind just starting off by sharing a little bit about who you are, your background, and what led you to medtech. [00:01:58] Kat Hurd: Yeah, absolutely. Well, medtech, I like to say it's always, I was kind of born into it. So my mom is a nurse and she ran a medical clinic when I was in middle school and high school. So truly I would go to the clinic after school and, if, if actually we didn't have school, I remember one of the days sitting in a pharmaceutical rep lunch presentation, so I really got exposed before I even knew what it was. Even in that moment, I wish I'd understood more of what that rep was doing and really dug deep. You know, I thought I was gonna go to school and be a doctor, and then I quickly realized I didn't like freshman bio. And I wanted something where I could have an impact but still have some flexibility. So I actually, my to, to take you back to like how this all started, my background, sports medicine and so my undergrad and graduate degrees are in exercise science. I used to be taping ankles and rehabbing knee injuries and doing all of those things. And then I got exposure through that of being in the operating room when our athletes would have, you know, the injuries that were being surgically repaired, and that was really where I got that secondary introduction into medical device and started having conversations with other people who'd made the transition from athletic training where you have a ton of, you know, in insight into the human body and understanding of the medical world. And moving that into the sales arena. And so I met with someone in Iowa City. I'm a University of Iowa grad, and he was running the western half of the US for Boston Scientific at the time. And one thing led to another, led to me flying to Arizona and interviewing and then moving their site unseen really. I was there for, you know, max of 24 hours total in my interview process. And I just packed two suitcases and said "I wanna break into medical device." And that was in 2010. And I just fell in love with the industry and the therapy. So I was in neuromodulation working directly with spinal cord stimulator patients and started as a clinical specialist, and then I really quickly realized the way to have very clear impact on patients and providers was really actually to be in that sales role and be the one directing the support, directing the resources. And in neuromodulation, because you're in the OR and actually programming the stimulator, you're also kind of supporting the patient's care, which for me was right in my wheelhouse. And then I moved into leadership. And you know what you really wanna know is probably how did I land where I am now? And so I spent 10 years or 11 actually at Boston Scientific. And then moved to Saluda Medical, so to commercialize a small Australian based startup here in the US, which was such a fun and unique opportunity. And I always knew that was gonna be more of a three to five year play, and I just had it on my heart that I wanted to build a business to help reps be better reps, because I believe that the quality of care and the quality of outcomes is also directly tied to the partnerships and the caliber of the industry that supports the therapies. [00:05:00] Lindsey Dinneen: Okay. I love that. And I have so many questions as a result, but okay, let's start a little bit with what you're doing now and then maybe, we'll, we'll get to some of the other stuff as well, but, so you're supporting reps, and I think you said something really impactful about a lot of the patient outcomes kind of goes back to how, how the reps can be the best they can be. So I'm curious what all goes into that for you and what kind of training or coaching do you provide? [00:05:31] Kat Hurd: Absolutely. You know, I really, I saw that squarely and believed it when I was a sales rep myself. So I spent the first six years of my career on the sales side of things, and then moved into being a sales leader. And as a sales leader and then an area Vice President Saluda, it was the thing that I saw of like our teams and our people that excelled the most, weren't just the best salespeople, but they were the people that understood how to, for lack of a better word, leverage that clinical and patient experience into the entirety of the sales process and sales cycle. So good clinical care and driving good sales conversations, levels up the partnership and really creating this layer of, not just being a partner, but being a trusted advisor with the providers that you work with. So how that translates into my business now, 'cause oftentimes, you know, I get the question of like, why did you leave a burgeoning career? I had one physician who was like, "You were gonna be a CEO. Like, why'd you leave medtech?" I'm like, "I didn't leave. I'm just doing it differently," because I saw so strongly and so clearly that having the right resources as a sales rep and at the right time as a sales rep changes your career. I was lucky to have great mentors, but there's things that if I had had the right support and resources at the right time, I could have been even, you know, faster or more impactful in my results. And so that's what I do now. What my business looks like now is really, you know, threefold. So I work directly with sales reps who, not through their companies, but they'll come to me directly and we do sales and leadership coaching. So working on the strategies in their business, how they're, you know, clinically supporting. But, you know, I, I leave the clinical nuts and bolts to the organization because I'm not an expert, and that, unless it's spinal cord stimulation, then we can talk that for days. But you know, really how they're leveraging their clinical prowess into their sales process and building systems for success. And then I work directly with companies helping train and elevate their talent, both on the sales and leadership level. Then I also have an arm of my business where I do, and that's kind of more of the consulting arm of my business. I also help with sales strategy and go to market strategy. And then I also do more of like corporate speaking. So keynotes and workshops and seminars really focused on both how do you build and grow your career in medtech, particularly as a woman, because we know there's just not a lot of us. And you know, part of what I'm so passionate about is helping everyone and raising the caliber of talent everywhere, but also making sure that women have the structure, the resources, and the idea of the systems that they need to create so they can go as far as they want to. Doesn't mean they have to go all the way to the C-suite level if that's not what they want, but to ensure that they have the representation and the pathway in front of them to understand how to get there. [00:08:27] Lindsey Dinneen: Excellent. Okay, so let's dive into that a little bit because I know, I know you're super passionate about helping, you know, in general the industry succeed and, and move forward. But yeah, you have a particular passion for helping women. And I'm curious what's, what are some of the challenges or differences you see in a woman as she's trying to build her career in this versus say, a man who might just have a, a different experience? [00:08:52] Kat Hurd: Yeah, very different lived experiences and a lot of the tools and tactics and strategies that I work with my clients on are pretty universal. But what isn't universal and what we really work on for my female sales leaders and sales executives is that mindset and approach. Because you both have to you, well, you have to understand one thing, how to navigate rooms where you're the only or the lonely. Because most often in medtech, you will find yourself, at some point in your career, and if you haven't, please call me. I wanna know who you are and talk to 'cause that would be amazing if you've never been in a room where you haven't been the only woman. But it, it requires nuance. It requires an understanding of how to position yourself and your insights in a way that they land. And land effectively with the decision makers that you build the right connections. So you have access and visibility, and that's really the internal corporate side of things. And then you have the customer facing where there's of course nuance of, I mean, I had, when I was a sales rep, I had three female physicians as customers over the duration of my career. So I needed to understand how to work closely and collaborate with male physicians and do it in a way that there was a clear and fast line of what that relationship and rapport was. And I was able to do that so successfully that not only did I win a bunch of awards, but many of those individuals have become friends and mentors and sponsors of mine as well. [00:10:22] Lindsey Dinneen: Wow, that's incredible. Yeah. I actually wonder if you could speak a little bit to what you just said, because this is something-- so recently I had an opportunity to host a leadership summit, and one of the things that came up in the keynote was about how there different types of mentorship available. So, so you need, you need people who are kind of in your corner coaching you, but then you also need that kind of next tier, which is that sponsor like you were saying. So I wonder if you could speak a little bit to that. [00:10:54] Kat Hurd: Absolutely. Mentorship and sponsorship is, is some of the best lighter fluid that you can add to your career growth, truly. And I'm so passionate about it, I, some of what I do from a consulting work standpoint is actually help organizations build mentorship programs. That was my very first consulting contract when I started my business. So I, I'm actually very proud of that and I, I don't ever share that, so thank you for asking that question. 'cause I don't think I would've even called that out. But it's so inherently valuable and I, I'll just take us on a quick sidebar of why it's so important especially for women, because women, when it comes to career growth, will wait until they have 100% of the qualifications to apply for a role. When left to our own devices, we oftentimes will look at it and say, "I either don't wanna be rejected, I don't wanna waste anyone else's time or my time, or, well, I don't have all of those qualifications, so I'm not going to apply. I'll wait." Now, our male counterparts are far more brazen and they need three out of five of those qualifications, and they are convinced they are the top candidate, and there's something to be said for that, right? You know, I, I aspire to that level of, of confidence and conviction and I, I, you know, really both, you know, encourage and in some ways push and, and motivate my clients to do, to take that mindset and approach and not just the unbridled confidence. We do need that. But to understand that you don't have to have every single checkbox because when you're looking at career growth, if you're fully qualified and can do everything of the entire job scope on day one, you've actually already entered a role that you're already overqualified for. [00:12:37] Lindsey Dinneen: Ooh. [00:12:39] Kat Hurd: Because where do you grow? [00:12:41] Lindsey Dinneen: Mm-hmm. [00:12:42] Kat Hurd: So, so that's, that's the importance of mentorship and sponsorship is to have others see maybe what you don't, and help you identify where your talents and where your strengths are. Because really career growth, the best thing you can do is lean into those talents and then explore the edges that you need to grow into, and mentorship can help you do that. Now, the difference between mentorship and sponsorship: a mentor is someone who's likely walked the same path or similar, has done much of what you've done or has insight into it, and can provide insight, guidance, resources, and be a sounding board. What you don't want is a mentor that just commiserates or tells you that everything you're doing is right, yeah, because we all have areas to grow. So that's, mentorship is so important to have those people that it's kind of your lifeline, right? Can you, what's your phone a friends? You gotta have some of those phone a friends. And then sponsorship, those are people that can help you open doors. And sometimes a mentor will also be a sponsor. They're not mutually exclusive, but those sponsors are individuals who have influence and access to rooms that you aren't in, as do your mentors oftentimes, but can help open doors create introductions and open pathways that you didn't even know existed. The mentors and sponsors alike will be those people to encourage you to apply for roles when you think, "Oh, I don't know, I'm, I'm not sure if I'm ready." I mean, that actually, as I said, that took me right back to, I was in Atlanta, Georgia when there was an area vice president role that opened up. I was a regional director at Boston Scientific at the time. And I went to my area vice president, who I worked for, and he's like, I was like, I don't know if I'm qualified. He's like, absolutely, you're applying. [00:14:28] Lindsey Dinneen: I love that and "I'm gonna follow up with you." [00:14:32] Kat Hurd: Yeah, yeah, exactly. And I didn't get the role, but that isn't the point. It's the conversations and the growth that even comes from it too. So, so sponsorship is so important because it really is what can create some of the access and avenues and opportunities that you didn't know were possible. I'll share kind of a quick illustration of that 'cause it's very relevant. Dr. Mike Dorsey, he has a, a society called Sierra Spine Society. Not sure if you're familiar it. [00:14:59] Lindsey Dinneen: Little bit. Yeah. [00:15:00] Kat Hurd: It's one of the best conferences out there. I'll just say that. Like you get to ski while you're there and it is wonderful. But when you talk about sponsorships, so I've known Mike through my career, especially as I moved to Saluda Medical, you know, expanded my sales leadership influence and the geographies that I supported. But when I went out and started my own business, he was the first one to come to me and say, Hey, I wanna partner with you. I want you to come to Sierra Spine and run an industry panel. [00:15:30] Lindsey Dinneen: Yeah. Yeah. [00:15:31] Kat Hurd: And there's no conversation like that that exists now. And we were texting about it this morning. It's why it's such a timely example, because now these conversations are, are popping up at other society meetings about the partnership, the collaboration, what is the role of industry and outcomes, all of those important things. And so his sponsorship has led to me now having other opportunities and conversations with different societies and different physician partners about the importance of those collaborations, about the accelerant that they can be in care and in, in outcomes. And so without someone like Mike, like Dr. Dorsey, I wouldn't have had that opportunity. I wouldn't have even had necessarily the proof of concept to go have these conversations. So that's where sponsorship can be so inherently valuable in your growth and creating movements and motions that you just truly didn't know were gonna be possible. [00:16:26] Lindsey Dinneen: Yeah, and I think you said something that I wanted to touch base about. So, you know, you were talking about how oftentimes women don't apply for positions because they don't meet all the qualifications. And I, I know that's a very common thing and something that I've heard from people that I've helped mentor are sometimes when they're young in their career or they're wanting to break into, say, medical device sales, sometimes they have all of these incredible skill sets, but because they're not already part of the industry, they feel that they're not always sure how to connect the dots and get seen. And I'm curious, what are some of the things that you recommend for young professionals who are in this spot trying to break in or trying to keep growing? [00:17:10] Kat Hurd: Yeah. Yeah. It's getting, gaining a clear understanding of your talents, your experiences, and how they translate to the person that's hiring is one of the most challenging and also most transformative things that you can do when you're searching to break into the industry. And so it's really, you know, having conversations with hiring managers before you're in an interview process. The job interview starts, the job application, the job opening, and you know, recruiting starts far before the opening is posted. So, step one, and I know that folks out there know this, but it's really, it's getting clearer on what facet of industry you wanna get into, understanding what those pieces are that you, that are, are critical in that role. Like what does that hiring manager really need? What are the problems they're looking to solve with that hire? And then translating your experience into the solutions that they're ultimately looking for. So what that like in said and simpler language, you have to be able to speak their language and understand their needs so you can position yourself as the solution to those needs. [00:18:31] Lindsey Dinneen: Do you think also there are some good resources out there that you would recommend in terms of, part of what I know the barrier can feel like, and, and it, it can be really daunting when you first get in the medtech industry because, for many reasons, but somebody might say an entire sentence where you're like, I have no clue what you're talking about, based on all of the industry jargon um, and acronyms and things like that. And so I'm wondering, are there resources available that, you know, people that are looking to break into the industry could access? [00:19:04] Kat Hurd: There are a ton of resources out there. The challenge is knowing the right resources. There's also a ton of programs that will support you in your breaking in. This is gonna be an unpopular opinion. I don't think you need big, expensive programs to create results. What you need is a strong belief in your candidacy and an understanding of what your gaps are. [00:19:29] Lindsey Dinneen: Mm-hmm. [00:19:31] Kat Hurd: And then the solutions and strategies of how to fill them. Now you can get there faster with the resources and framework. I mean, I don't have a formal program, but I still help people on a, you know, one-off basis break into the industry. But at a broader level, I think what you're really asking is how does someone, it's kinda like eating an elephant. Like where do you, where do you take the first bite? You have to get started in knowing what you don't know. And so truly, I would encourage people if you're looking to break into the industry, to sit down and make a list of all the things that you don't know about the medical device industry. And that might be what are the different, you know, verticals of the industry? What are even the, you know, the specialties or the therapies and then, okay, so "I don't know even what space I would want to get into." That's, you know, bullet number one to identify. Then, "I don't know the language or terminology." That's an easy one to fix. I used to always tell candidates that go take an online medical terminology class. Learn to speak the language. I feel like they're out there for like 20 bucks or something. You can find really easy ones. I'm sure you could do free ones. You could probably ask chatGBT to create you, you know, a laundry list of acronyms and medical terminology and an understanding. Because when you understand the environment, that's when you can translate your experience into something that's relevant. But when you don't understand the environment the customers work in, what the needs are of the hiring manager and what the positioning is of the company, it becomes really hard to position yourself as the right candidate. So to go back to like, what are those resources? Absolutely. There's, there are folks that do some free programs. I mean, honestly, TikTok, there's a ton of people dropping knowledge on TikTok. There's some YouTube channels out there. I'm actually recording kind of a mini podcast series this week with Jay Pendleton, who's another. You know, big name in the medical device space, but adjacent to medical device from an industry standpoint, where we're gonna be talking about a lot of this because there is such a need, and the most important thing is first you identify the gaps and then you go find those resources. Of course, AI is a great place to go, but also have those human connections, make that outreach because that actually will help you then in your job search as well. [00:21:47] Lindsey Dinneen: Right, exactly. And then making those connections. I always say you never know where that'll lead. You just, you don't, you might think it's just a quick intro and, and that's fine, but then your, your name will come to mind from if somebody's hiring or needs something. It's just, yeah, that, that's great advice. So, one of the things I wanted to ask about is you do a lot outside of, you know, your full-time job, which I'm sure feels more, even more full-time now, uh, running your own business. But tell us a little bit about some of the things that you're passionate about outside of full-time work that you volunteer for. [00:22:25] Kat Hurd: Yeah. It, it's funny you say that, you know, the, the, the full-time job now is definitely like an all-time job, not just a full-time job, but I love it. So I hate to be that person that's like, it doesn't feel like work when you love what you do, but I loved what I did before, you know, this is a new way of me doing it. But I also firmly believe that the, and I've seen it in my business, the best years I had as a sales rep and as a sales leader were the years where I wasn't just giving to my team and to my organization but was also connected and giving to my community as well. So right now, that looks like me spending a ton of time at Ballet Arizona. I'm the Vice Chair of the board of directors, so I have, I committed to a four year leadership, yeah, leadership journey with them. So I have two years as vice chair and then I'll be Board Chair for two years. And it's just really, you know, I've been dancing since I was itty bitty. I had a short stint on the Phoenix Suns for a hot minute, and you know, it's been something that has been creatively my kind of happy place since I was little. And it's been really fun to take my business acumen and my strategic mind and get to apply it to the art form that I love. So that's where, you know, these days where I'm spending a lot of my time, but I also do rescue work and work at our local animal shelter, walking dogs, giving them treats, you know. There's something to be said for walking in after a long day or a long week to, and yes, people often are like, it's so sad. How can you do that? Those dogs are so happy to see you, there is no way, truly no way that you can leave pissed off. Like, it just, it takes the, the weight of the week or whatever the situation is, and shifts your mind and shifts your perspective because truly I think when we, you know, come from a head space of gratitude, because we are all so lucky to be in the medtech world, the opportunities that we have, the, you know, just uncharted territory really that our career can take. That's the best part. I'm sure you didn't imagine that you would have a podcast and you would have, you know, the influence that you do with MD&M and all these other opportunities that are afforded to you. And so, it's good to be reminded of how much we do have, and it never hurts to get some puppy kisses too. [00:24:42] Lindsey Dinneen: Exactly. Well, you're speaking my language on both of them. [00:24:46] Kat Hurd: Love that. [00:24:46] Lindsey Dinneen: When we were, when my husband and I were paused for a little while in Oregon, we would go and do and go walk dogs and, and yeah, it is, it is hard because you kind of fall in love instantly all the time, but it is such a, it's so, it's such a gift. It's a gift for you. [00:25:02] Kat Hurd: Yeah. It, it really is. And we foster failed twice, so, yeah. You know, so we probably just should admit that we aren't good fosters we're good, you know, pet parents, but it is, and even you can't take all of them home with you. So just, you know, having those moments with them is really fun. [00:25:21] Lindsey Dinneen: So you mentioned your business acumen being wonderfully applied to the arts world, which is a, which is so great. I'm also wondering how it's worked on the opposite side of things. Like what do you think dance taught you growing up that you apply? [00:25:37] Kat Hurd: I love this question, and I was just saying this last week. I sat down at dinner with a mentor and sponsor of mine, and I was telling him that I am convinced --you cannot convince me otherwise-- that my dance background-- 'cause I actually, I went as far as to get a degree in dance. So like I live and breathe it for for a long time. And that is what made me such a successful sales rep especially in the OR environment because what do you do as a dancer? You observe patterns of movement and you, you are, you can predict what's going to happen physically before it happens because you can read those cues and so that is exceptionally valuable in the OR when as a sales rep, your job is to be like bright and present when they need you, and blend into the background when they don't. And it is like a dance in the OR, it's absolutely choreographed. And then when that goes into sales conversations, it's reading the nonverbals and understanding what someone's body positioning and posture is telling you without their words. And you really do, especially I, I did a lot of modern dance in college, you learn that improvisation, you have to be able to read someone's movement before it happens. So yes, it's a great question and I, I, you know, strongly believe, I know that athletes often get hired as medical device reps, but I think dancers are just an untapped and really under leveraged subset of talent because their skills can translate so strongly. [00:27:09] Lindsey Dinneen: I love that. Well, shout out to dance is I think many of the listeners know I'm also a dancer, so I of course, feel very strongly about the connection and the power that the arts can provide for any career really. [00:27:23] Kat Hurd: Truly. I'm curious for you, what do you feel like your, if of your background, right, of your maybe it's dance or some of the volunteer work or the travel that you do, how has that positioned you in your current career for success? [00:27:36] Lindsey Dinneen: Oh, that's, that's a fun one. I think so I think all of the skills that I learned as a dancer have been instrumental. Things like learning how to take correction with grace and apply, apply it quickly, apply the feedback quickly, permanently to make a big difference. I think learning teamwork and how you fit into the broader picture as a whole, you're not always gonna be the soloist or kind of the leader in charge necessarily. So sometimes you have to know when you're gonna be to put in dance terms, the corps de ballet. You have to know when to be the main group of dances. But again, not feeling like any role is insignificant. We all work together to success. I also think that resilience is a huge component of it. The grit that is required for dancing translates so well into anything else because this industry can be difficult and like you said, depending on where you're navigating, and what you wanna do, sometimes it takes a lot of sort of persistence and, and resilience and grit. Yeah, I could go on and on, but those are things that come immediately to mind. [00:28:48] Kat Hurd: Yeah, absolutely. It's that resilience. I mean, when you take it back to the conversation about breaking into the industry, you have to be willing to-- and same as in arts or in athletics-- like be willing to let yourself fail, to push yourself to your edges, to understand your limitations, and then blow past them. Because if you just stay at what your limitations are, you're never really gonna get where you wanna go. And as a dancer, you have to live that life all the time. And it is, it's absolutely, those are the hallmarks to breaking in. You have to be agile. You have to be very comfortable with rejection. You have to be very gritty in trying and trying and trying again, and it doesn't matter how many times you don't get a response, you're still gonna send out those messages. You're still gonna ask people for coffee chats. You're still gonna send one question to one person and ask for three minutes of their time. [00:29:39] Lindsey Dinneen: Yep. Yep. I love it. All right, so I'm curious, as you've had a really cool career in this industry, what are, what is a moment maybe that stands out as really solidifying that, "Hey, I'm, I'm in the right place at the right time." [00:29:54] Kat Hurd: Oh man, that's a hard question. I love that because I feel like I've had so many of those moments, and interestingly, it's not the moment that have been, you know, me standing on stage accepting an award. I think it's been in the little moments, like those quiet whispers of like, " Yes, this is it." You know, the, the times where my customers, you know, as a sales rep would come to me and say, "Here's the challenge I'm having. What are your thoughts?" Not about spinal cord stimulation, but because we built this trusted partnership and, you know, and I became an advisor in their world and not just another rep, right? So like those moments as a sales rep really were the moments that were were those kind of inflection points for me. And then I look as a sales leader of seeing my team win as a coach. You know, I, I get the question of like, well, you know, how did you prepare for what you're doing now? I'm like, "Guys, I'm coaching. I was coaching people for the last 10 years as a sales leader. Now I just do it for my own company instead of others." You know, but, and I will say this. The moment I knew that I was on the right path in my, my current role in starting my own company was starting to see the impact that it would have on the reps that I was working with. The sales leader who came to me as she first got promoted and then now is currently ranked first in her company, you know, like the, the reps-- even just this last weekend I got a text message from a rep I hired a few years back and who's at a different company doing big things and they just won a massive onstage award as Rookie of the Year. You know, really cool moments that getting to be a part of their success and their journey because not only is it incredibly fulfilling do you get to make a, a massive impact, but it also financially sets you and your family up for massive opportunity ahead. You know, I just had a client where we negotiated an additional 25K on her offer. Like that's a big deal, right? [00:31:58] Lindsey Dinneen: Wow. Yeah. Yeah. That's huge. [00:31:59] Kat Hurd: So, so I apologize because I didn't give you just one moment because, for me, it's, it's the invisible thread that runs through and that, because that thread has always been present in a different form or fashion, it's given me this in some ways insane courage to do things that people think are, are delusional and know that it's the right thing because of the impact that it's gonna have. [00:32:24] Lindsey Dinneen: Love it. Absolutely love it. Okay, so pivoting the conversation just for fun, imagine that you were to be offered a million dollars to teach a masterclass on anything you want. It could be within the industry or what you're doing now, but it doesn't have to be. What would you choose to teach? [00:32:42] Kat Hurd: Anything I want? Oh my gosh. Can I give two answers? Good. Because the first thing I would absolutely just want to teach one on this industry, and that's the power of influence in building your net, your web, I call it your, your web of, of influence. That changes your career. It's who you, who knows you, what they know of you, and that is what opens doors. So I feel like I would, I would do that. Right. And I, I have to do that because that's really what I'm so passionate about. But if it was like any off the wall topic, it would be traveling to Europe on a budget. I have it on lock. And particularly how to do the long haul flights without jet lag. [00:33:35] Lindsey Dinneen: Oh, excellent. [00:33:37] Kat Hurd: Yeah. [00:33:38] Lindsey Dinneen: Might need to talk more about this offline. [00:33:41] Kat Hurd: I feel like I have such a system and one of my my last boss used to always say, he's like, "You can go," 'cause I international travel is my, like, my passion outside of dance. And he's always like, "You can go, you just have to promise me that you'll come back." He used to joke. He's like, "I'm afraid that one day you just won't come back." So I made good on my word. I always came back, but I did learn a lot of tips and tricks along the way. [00:34:07] Lindsey Dinneen: Awesome. Excellent. Great masterclass topics. How do you wish to be remembered after you leave this world? [00:34:15] Kat Hurd: Oh, I love that. And what it unique question to ask in a podcast about medtech. I, I think we get so stuck in talking about who we are as professionals, that we don't always talk about the bigger pieces. So I wanna be remembered as someone who cared deeply and made an impact on others. Yeah. [00:34:35] Lindsey Dinneen: Yeah. Yeah. I love that. And you're well on your way, so there you go. [00:34:41] Kat Hurd: I like to think so. It's all a work in progress and it's truly a testament to, you know, to take it back to some of the start of our conversation to the mentors and sponsors I've had along the way who have given me-- you know, I, I talk about borrowed belief a lot because there's gonna be times in your career where you don't think you have what it takes. And that's where mentors and sponsors come in. And having people that will loan you their belief in you, so you can believe in yourself, even just for a moment to go do the thing that feels really scary. And because I've had those people, you know, I've I've felt brave enough to take those risks and moments. [00:35:17] Lindsey Dinneen: Love it. Yeah. Excellent. All right. And then final question. What is one thing that makes you smile every time you see or think about it? [00:35:26] Kat Hurd: Oh my gosh. Well, at the risk of sounding like that dog lady, it's a hundred percent our pups. We have, we have two now, and our current foster slash foster fail has this unbridled energy that I always look at her and think, "Gosh, if I could bottle that." Yes. So yeah, it's my family, right? My partner, Matt. I think that those, it's those moments. At the end of the day, I couldn't do what I do without my family, without Matt and yeah, so I'm very lucky to have them. [00:35:55] Lindsey Dinneen: Love that. Excellent. Well, this has been an amazing conversation, Kat, and we are so honored to be making a donation on your behalf as a thank you for your time today to Save the Children, which works to end the cycle of poverty by ensuring communities have the resources to provide children with a healthy, educational, and safe environment. So thank you so much for choosing that charity to support, and also thank you for continuing to work to change lives for a better world. We're grateful, and I wish you the most amazing continued success. [00:36:30] Kat Hurd: Well, Lindsey, thank you for all that you're doing as well. Even hosting these conversations, it's such an important, you know, distinction to talk about how do you make a difference in this space and change things for the better. So thank you for your kind words and the opportunity to have this conversation, get to hang out with you for a little bit. And yeah, I look forward to our next conversation. [00:36:50] Lindsey Dinneen: Awesome. All right. Thank you. [00:36:53] Dan Purvis: The Leading Difference is brought to you by Velentium Medical. Velentium Medical is a full service CDMO, serving medtech clients worldwide to securely design, manufacture, and test class two and class three medical devices. Velentium Medical's four units include research and development-- pairing electronic and mechanical design, embedded firmware, mobile app development, and cloud systems with the human factor studies and systems engineering necessary to streamline medical device regulatory approval; contract manufacturing-- building medical products at the prototype, clinical, and commercial levels in the US, as well as in low cost regions in 1345 certified and FDA registered Class VII clean rooms; cybersecurity-- generating the 12 cybersecurity design artifacts required for FDA submission; and automated test systems, assuring that every device produced is exactly the same as the device that was approved. Visit VelentiumMedical.com to explore how we can work together to change lives for a better world.

In this episode, Stafford sits down with Terry Roberts, a man who spent decades navigating the corporate world with companies like IBM, Procter & Gamble, Kimberly-Clark, Boston Scientific, and Medtronic only to walk away and bet on himself.After realizing in his mid-50s that corporate advancement had a ceiling, Terry made a hard pivot. No safety net, no guarantees. Just a decision to learn real estate from scratch. Over the next several years, he built a portfolio strong enough to replace his income and step away from corporate life on his own terms.Now semi-retired, Terry shares what that transition really looked like; the uncertainty, the discipline, and the long game most people aren't willing to play. This is a conversation about reinvention, knowing when to pivot, and building something that actually gives you freedom.Outside of business, Terry is a family man first. He's been married to his college sweetheart Gina for over 40 years, with three daughters, a growing crew of grandkids, and a life centered around family, faith, and Mississippi State athletics. You'll usually find him at a game, at the lake house on the Tombigbee, or in the shop working with his hands.He also co-hosts the Cardiovascular Matters podcast alongside Dr. Craig Walker, where they dig into heart health and real-world medical insights.This one's about what happens when you stop waiting for permission and start building your own path.

Today I sit down with Kelly Abbott, one of my absolute best friends and someone I have known for more than 20 years, and we get into a conversation I think all of us need to be having right now. Kelly is one of the most talented CIOs, internet entrepreneurs, and technology minds I know, and what I appreciate most about him is that he does not approach AI like a hype man. He approaches it like a builder, an artist, a strategist, and a deeply curious human being. That combination is rare. What really stands out to me in this conversation is that Kelly is not using AI in a shallow, gimmicky way. He is exploring how it can become a genuine creative partner. He walks me through a project he has built called Writer's Room, a tool designed to simulate the collaborative energy of a real writers room so people can develop long-form fiction with multiple AI personas, story structure, quality control, continuity, and creative tension built in. It is a fascinating example of what becomes possible when you stop thinking about AI as a shortcut and start thinking about it as a thought partner. We also talk about the AI-generated video he created for Seven CTOs, and this part of the conversation opens up something deeper than tools alone. Kelly shares how he used AI to translate an inner idea into a full creative artifact by scripting with ChatGPT, shaping voice in ElevenLabs, experimenting with music, and embracing imagery, archetype, and non-deterministic outputs along the way. One of the most powerful parts of this conversation is hearing him describe why he chose an unexpected narrator voice and how he thinks about the relationship between text, emotion, music, image, and trust. It is a masterclass in taste, not just tech. We also get honest about the tension many people feel around AI. I say in the episode that I am less worried about AI destroying the world by itself than I am about people using it stupidly and at scale. Kelly does not brush that off. He agrees that the concern is real, and he makes a strong case that the answer is not avoidance. The answer is learning. He talks about why he teaches Claude in particular, why he respects Anthropic's stance on safety, and why becoming capable with these tools puts you in the driver's seat instead of leaving you vulnerable to being outpaced by them. Another piece I love is that this conversation is not just about AI in the abstract. It becomes personal. Kelly starts exploring what it could look like to use tools like NotebookLM to understand my body of work more deeply, surface the real pain points my clients face, and eventually help build something like an on-demand “Johnny brain” people could interact with for coaching and insight. That is where this episode gets especially exciting to me, because it moves from fascination to application. We are not just asking what AI is. We are asking how to use it in service of real communication, real creativity, real usefulness, and real human connection. And then, because life is funny and friendship matters, we close by telling the story of how Kelly and I first met on a flight to South by Southwest. It starts with him defending an empty seat, me walking back up the aisle in a too-tight Flash T-shirt, and Kelly greeting me with, “I don't like you very much right now.” What followed was a conversation, a weekend, and a friendship that has lasted for decades. Honestly, that ending says a lot about this whole episode. Beneath all the tools and ideas is something more important: curiosity, candor, play, and the willingness to engage what is right in front of you. This episode matters because AI is not coming someday. It is here. And like it or not, all of us need to get familiar with what it can do, where it helps, where it misleads, and how to use it without giving up our judgment, our values, or our originality. That is why I expect this to become a semi-regular part of the podcast.   Key Takeaways AI becomes far more useful when you treat it as a creative partner rather than a magic shortcut. Kelly's “Writer's Room” concept shows how AI can simulate diverse voices, roles, and editorial functions to strengthen storytelling and idea development. A learner's mindset still matters as much as any tool. Kelly says one of his advantages has always been being “a page ahead in the manual” because he stayed up learning. Great AI output still depends on human taste, curation, and judgment. The tools can generate, but the human being still has to choose. Non-deterministic outputs are not always a flaw. In creative work, unpredictability can actually produce something more alive and surprising. Voice, music, and image are not separate from strategy. They shape trust, tone, and emotional impact. AI literacy is quickly becoming a real professional advantage. The people who learn how to use these tools well will be far less likely to be overwhelmed by them. Safety matters. Kelly makes a clear distinction between powerful use and careless use, which is one reason he emphasizes Claude and Anthropic's public posture around AI safety. The future is not only about automating tasks. It is also about making your ideas more discoverable, more creative, and more accessible to the people you serve. Friendship, curiosity, and long conversations still matter. Some of the best ideas begin with a human relationship, not a prompt.   Addressing Relevant Issues This conversation touches a nerve that a lot of people are feeling right now. We are living through a moment where AI is moving faster than most people can comfortably track, and that creates a strange mix of excitement, intimidation, skepticism, and risk. This episode speaks directly to that. We get into leadership, creativity, communication, entrepreneurship, technology, safety, and discernment. We also touch the deeper issue underneath all of it, which is whether we are going to let technology flatten our humanity or help us express it more powerfully. To me, that is the real issue. Not whether AI exists, but whether we develop the judgment, character, and skill to use it well.   Why This Episode Matters This episode matters to me personally because Kelly is not just a brilliant technologist. He is someone I trust. That matters a lot in a space where there is so much noise, so much hype, and so much confident nonsense. What really stands out to me is that Kelly brings both depth and play to this conversation. He understands the technical side, but he also understands voice, story, aesthetics, and what makes something actually resonate. I think listeners will come away with something rare here: not just more information about AI, but a healthier and more useful way to think about it. And honestly, I care about this because I do believe we all need to start getting familiar with what these tools can do. The people who learn thoughtfully are going to be in a much stronger position than the people who ignore this and hope it goes away.   Resources Mentioned Writer's Room Studio — https://writersrooms.studio/ Kelly's AI video — https://www.youtube.com/watch?v=XteCrxWZIvA ElevenLabs — https://elevenlabs.io/ Mother / music sample generation invite — https://mother.is/invite/USER-D071D3FA Ideogram — https://ideogram.ai/ Google Flow — https://labs.google/fx/tools/flow NotebookLM — https://notebooklm.google.com/ BOL Agency — https://www.bol-agency.com/ The K State — https://thekstate.com/   Connect & Subscribe If this conversation gave you something to think about, subscribe to Live Like a Leader, leave a review, and share this episode with someone who is trying to make sense of AI, leadership, creativity, or where communication is headed next.   Next Steps A good next step is to spend a little time with Kelly's work and then actually try one of the tools we discuss. Don't just have an opinion about AI from a distance. Get your hands on it. Explore it. Test it. See where it helps, where it falls short, and where your own judgment needs to get stronger. And if this conversation resonates, stay with us, because this is going to be an ongoing part of the show. -----   Kelly Abbott is Chief AI Officer at BOL Agency and founder of K-State LLC, where he helps organizations stop talking about AI and start operating with it. A two-time exit founder (Match.com, Adobe), Kelly now builds AI-native systems for marketing agencies, law firms, and enterprise teams. He trains teams on Claude, designs agentic workflows, and creates products at the intersection of AI, music, and creative technology. He lives in Washougal, WA with his family. Ohio State alum. Still writing stories. --------John Bates provides 1:1 Executive Communications Coaching, both in-person and online. He also gets 92+ Net Promoter Scores for his large and small group leadership development trainings at organizations like Johnson & Johnson, NASA, Google, Intuit, Boston Scientific, and many more. Find more at https://executivespeakingsuccess.com.Sign up for his weekly micro-trainings for free at https://johnbates.com/mini-trainings and create a great leadership communications habit that makes you the kind of leader who inspires trust, loyalty, and connection.

Prabagar Sankar, Senior Engineer at Intuitive, a leader in robotic-assisted healthcare innovation, shares a front-line perspective on how healthcare innovation actually makes it from lab to patient. We explore the critical role of concurrent engineering and early stakeholder alignment in bridging the gap between technical breakthroughs and real-world, regulated deployment. With experience spanning wearable health technologies, medical device R&D, and clinical research across organizations like Sonova, Boston Scientific, and Drexel University, Prabagar dives into how clinician–engineer collaboration drives adoption, and why the future of healthcare lies at the intersection of sensors, data, AI, and robotics. He also unpacks the shift from reactive care to proactive and preventative medicine, powered by continuous monitoring and smarter systems. From wearable sensors to scalable medical devices, this conversation highlights what it takes to build technologies that are not only innovative—but safe, effective, and truly impactful for patients.

From $50k to $115k: How a Ministry Director Broke into Medical Sales (and Survived a Major Setback)Can you pivot from a nonprofit background to a six-figure medical device sales role? Kevin Maher did—but it wasn't a straight line. From landing a dream $115,000 offer at AstraZeneca to having it rescinded over a driving record error, this is the raw, unfiltered truth about the medical sales journey.In this episode of Medical Sales U, Kevin Maher and I dive deep into the grit, the "corporate game," and the exact steps needed to land a role at top companies like Applied Medical.What You'll Learn in This Episode:The "Panera Strategy": How Kevin hunted down a hiring manager in real life.Transferable Skills: Why ministry, teaching, and coaching are "secret weapons" for sales.The Driving Record Warning: The $115k mistake you MUST avoid before you apply.The "Corporate Game": How to balance radical authenticity with professional wisdom.Clinical Interviewing: A look inside the Applied Medical vNOTES procedure test.Timestamps:0:00 - Introduction: Kevin's transition from Young Life to Med Sales.04:20 - The skill set: Why "Area Directors" make great Territory Managers.08:15 - Networking 101: Finding an AstraZeneca manager at Panera Bread.16:30 - The $115k Offer: Doubling a salary overnight.18:45 - DISASTER: Why the offer was rescinded (and how to fix your record).22:10 - The Grind: Delivering bulletins and taking calls from the car.27:50 - Learning from Rejection: Failing the Boston Scientific final round.31:15 - The "Corporate Game": When to be authentic vs. when to be wise.36:40 - Success at Applied Medical: The vNOTES clinical interview.41:20 - Final Advice: Perseverance and the future of Medical Sales.Connect with Us:Follow Kevin Maher on LinkedIn: https://www.linkedin.com/in/kevinmaher1/About Medical Sales U:We help high-performers—teachers, nurses, and professionals—break into the medical device and pharmaceutical sales industry through expert coaching and a proven community of winners. We help professionals transition into top-tier medical sales roles: medicalsalesu.com/#MedicalSales #CareerPivot #MedicalDeviceSales #AstraZeneca #JobInterviewTips #SalesCareer #MedicalSales

Send us Fan MailMustafa Poonawala is a globally recognized leader in medical device and diagnostics innovation, known for his ability to translate strategy into execution across R&D, clinical operations, and portfolio management. Over a career spanning more than two decades, he has built and led world-class engineering and program teams, guided products from early development through regulatory approval, and driven large-scale organizational transformation in highly regulated environments.Currently, Mustafa is the CEO of DynaMill Research, a specialized Clinical Research Organization focused on helping diagnostics companies dramatically reduce cycle times and improve cost predictability. DynaMill's approach blends agile program management, end-to-end digital clinical workflows, predictive enrollment strategies, and deep partnerships with multi-site clinical networks. The goal is simple but ambitious: help diagnostic innovations reach patients faster without sacrificing rigor or quality.In parallel, Mustafa is Managing Partner at Steps Program Management, where he has spent nearly a decade advising organizations on agile transformation, PMO maturity, and portfolio optimization—particularly within medical device R&D. His work emphasizes lean, value-driven processes, difficult prioritization, and delivery predictability, all grounded in real-world execution rather than theory.Previously, Mustafa held senior leadership roles at BD, Hospira, OBS Medical, and Boston Scientific. His experience spans implantable and disposable devices, complex electromechanical systems, software and cybersecurity for safety-critical systems, and large-scale diagnostics portfolios exceeding billions of dollars in revenue. With a PhD in Software Engineering focused on safety-critical systems, Mustafa brings a rare blend of deep technical rigor, business acumen, and servant leadership to every challenge he tackles.LINKS:Guest LinkedIn: https://www.linkedin.com/in/mustafapGuest website: https://dynamillcro.comAaron Moncur, host Subscribe to the show to get notified so you don't miss new episodes every Friday.The Being An Engineer podcast is brought to you by Pipeline Design & Engineering. Pipeline partners with medical & other device engineering teams who need turnkey equipment like cycle test machines, custom test fixtures, automation equipment, assembly jigs, inspection stations and more. You can find us at www.teampipeline.usWatch the show on YouTube: www.youtube.com/@TeamPipelineus 

Scott Wapner and the Investment Committee discuss the state of stocks with no signs of an end to the war. The experts detail their latest portfolio moves. Calls of the Day include Robinhood, Boston Scientific, Bristol-Myers Squibb, and American Express. The desk debates Evercore's new list of "stocks for stability." Michael Santoli joins with his Midday Word. Investment Committee Disclosures   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.